Microbot Medical (MBOT) S-1 4 Feb 25 IPO registration Financial data

Cover

Cover	9 Months Ended
	Sep. 30, 2024
Entity Addresses [Line Items]
Document Type	S-1
Amendment Flag	false
Entity Registrant Name	MICROBOT MEDICAL INC.
Entity Central Index Key	0000883975
Entity Tax Identification Number	94-3078125
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	288 Grove Street
Entity Address, Address Line Two	Suite 388
Entity Address, City or Town	Braintree
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02184
City Area Code	(781)
Local Phone Number	875-3605
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	288 Grove Street
Entity Address, Address Line Two	Suite 388
Entity Address, City or Town	Braintree
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02184
City Area Code	(781)
Local Phone Number	875-3605
Contact Personnel Name	Harel Gadot

Interim Condensed Consolidated

Interim Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 479	$ 2,468	$ 2,442
Marketable securities	3,859	3,917	5,760
Short-term deposit			3
Restricted cash	48	49	77
Insurance recovery receivable related to legal settlement and legal expenses		1,335
Prepaid expenses and other current assets	609	152	532
Total current assets	4,995	7,921	8,814
Property and equipment, net	99	146	221
Operating right-of-use assets	114	260	502
Total assets	5,208	8,327	9,537
Current liabilities:
Accounts payable	246	357	116
Lease liabilities	65	191	283
Legal settlement accrual		2,211
Accrued liabilities	1,060	1,027	1,670
Total current liabilities	1,371	3,786	2,069
Non-current liabilities:
Long-term lease liabilities	29	40	179
Total liabilities	1,400	3,826	2,248
Commitments and contingencies
Shareholders’ equity:
Common stock; $0.01 par value; 60,000,000 shares authorized; 16,651,433 and 11,707,317 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively	168	118	80
Additional paid-in capital	91,192	83,884	75,970
Accumulated deficit	(87,552)	(79,501)	(68,761)
Total shareholders’ equity	3,808	4,501	7,289
Total liabilities and shareholders’ equity	$ 5,208	$ 8,327	$ 9,537

Interim Condensed Consolidat_2

Interim Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.01	$ 0.01	$ 0.01
Common stock, shares authorized	60,000,000	60,000,000	60,000,000
Common stock, shares issued	16,651,433	11,707,317	7,890,628
Common stock, shares outstanding	16,651,433	11,707,317	7,890,628

Interim Condensed Consolidated

Interim Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Research and development, net	$ 2,060	$ 1,612	$ 4,646	$ 4,594	$ (5,724)	$ (7,736)
General and administrative, net	1,240	932	3,549	3,193	(4,131)	(5,545)
Operating loss	(3,300)	(2,544)	(8,195)	(7,787)	(9,855)	(13,281)
Financing income, net	85	98	144	201	228	118
Loss on disposal of property and equipment					(2)	(5)
Loss on legal settlement, net					(1,111)
Net loss	$ (3,215)	$ (2,446)	$ (8,051)	$ (7,586)	$ (10,740)	$ (13,168)
Basic net loss per share	$ (0.20)	$ (0.21)	$ (0.53)	$ (0.79)	$ (1.05)	$ (1.81)
Diluted net loss per share	$ (0.20)	$ (0.21)	$ (0.53)	$ (0.79)	$ (1.05)	$ (1.81)
Basic weighted average common shares outstanding	16,471,419	11,707,317	15,129,574	9,653,337	10,199,984	7,260,344
Diluted weighted average common shares outstanding	16,471,419	11,707,317	15,129,574	9,653,337	10,199,984	7,260,344

Interim Condensed Consolidate_2

Interim Condensed Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands		Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balances at Dec. 31, 2021		$ 72	$ 69,902	$ (55,593)	$ 14,381
Balance, shares at Dec. 31, 2021		7,108,133
Issuance of common stock and warrants net of issuance costs	[1]	$ 8	4,316		4,324
Issuance of common stock and warrants net of issuance costs, shares	[1]	782,495
Share-based compensation			1,752		1,752
Net loss				(13,168)	(13,168)
Balances at Dec. 31, 2022		$ 80	75,970	(68,761)	7,289
Balance, shares at Dec. 31, 2022		7,890,628
Share-based compensation			412		412
Net loss				(2,853)	(2,853)
Issuance of common stock upon exercise of warrants		$ 3	(3)
Issuance of common stock upon exercise of warrants, shares		240,000
Balances at Mar. 31, 2023		$ 83	76,379	(71,614)	4,848
Balance, shares at Mar. 31, 2023		8,130,628
Balances at Dec. 31, 2022		$ 80	75,970	(68,761)	7,289
Balance, shares at Dec. 31, 2022		7,890,628
Net loss					(7,586)
Balances at Sep. 30, 2023		$ 118	83,587	(76,347)	7,358
Balance, shares at Sep. 30, 2023		11,707,317
Balances at Dec. 31, 2022		$ 80	75,970	(68,761)	7,289
Balance, shares at Dec. 31, 2022		7,890,628
Issuance of common stock and warrants net of issuance costs	[2]	$ 38	6,520		6,558
Issuance of common stock and warrants net of issuance costs, shares	[2]	3,816,689
Share-based compensation			1,394		1,394
Net loss				(10,740)	(10,740)
Balances at Dec. 31, 2023		$ 118	83,884	(79,501)	4,501
Balance, shares at Dec. 31, 2023		11,707,317
Balances at Mar. 31, 2023		$ 83	76,379	(71,614)	4,848
Balance, shares at Mar. 31, 2023		8,130,628
Issuance of common stock and warrants net of issuance costs		$ 35	6,523		6,558
Issuance of common stock and warrants net of issuance costs, shares	[3]	3,576,689
Share-based compensation			349		349
Net loss				(2,287)	(2,287)
Balances at Jun. 30, 2023		$ 118	83,251	(73,901)	9,468
Balance, shares at Jun. 30, 2023		11,707,317
Share-based compensation			336		336
Net loss				(2,446)	(2,446)
Balances at Sep. 30, 2023		$ 118	83,587	(76,347)	7,358
Balance, shares at Sep. 30, 2023		11,707,317
Balances at Dec. 31, 2023		$ 118	83,884	(79,501)	4,501
Balance, shares at Dec. 31, 2023		11,707,317
Issuance of common stock and warrants net of issuance costs	[3]	$ 17	2,380		2,397
Issuance of common stock and warrants net of issuance costs, shares	[3]	1,685,682
Share-based compensation			529		529
Net loss				(2,371)	(2,371)
Issuance of common stock relating to settlement agreement	[4]	$ 10	1,101		1,111
Issuance of common stock relating to settlement agreement, shares	[4]	1,005,965
Balances at Mar. 31, 2024		$ 145	87,894	(81,872)	6,167
Balance, shares at Mar. 31, 2024		14,398,964
Balances at Dec. 31, 2023		$ 118	83,884	(79,501)	4,501
Balance, shares at Dec. 31, 2023		11,707,317
Net loss					(8,051)
Balances at Sep. 30, 2024		$ 168	91,192	(87,552)	3,808
Balance, shares at Sep. 30, 2024		16,651,433
Balances at Mar. 31, 2024		$ 145	87,894	(81,872)	6,167
Balance, shares at Mar. 31, 2024		14,398,964
Issuance of common stock and warrants net of issuance costs	[5]	$ 16	2,006		2,022
Issuance of common stock and warrants net of issuance costs, shares	[5]	1,566,669
Share-based compensation			331		331
Net loss				(2,465)	(2,465)
Balances at Jun. 30, 2024		$ 161	90,231	(84,337)	6,055
Balance, shares at Jun. 30, 2024		15,965,633
Share-based compensation			283		283
Net loss				(3,215)	(3,215)
Issuance of common stock under the at-the-market offering program, net of issuance costs	[6]	$ 7	678		685
Issuance of common stock under the at-the-market offering program, net of issuance costs, shares	[6]	685,800
Balances at Sep. 30, 2024		$ 168	$ 91,192	$ (87,552)	$ 3,808
Balance, shares at Sep. 30, 2024		16,651,433
[1]Net of issuance costs in the amount of $ 676 1,075 333 328 49

Interim Condensed Consolidate_3

Interim Condensed Consolidated Statements of Shareholders' Equity (Parenthetical) - USD ($) $ in Thousands	3 Months Ended			12 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement of Stockholders' Equity [Abstract]
Net of issuance costs	$ 49	$ 328	$ 333	$ 1,075	$ 676

Interim Condensed Consolidate_4

Interim Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Operating activities:
Net loss	$ (8,051)	$ (7,586)	$ (10,740)	$ (13,168)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation of property and equipment	65	71	106	102
Loss on legal settlement			2,211
Insurance recovery related to legal settlement			(1,335)
Interest income and unrealized gains from marketable securities, net	(2)	(105)	(160)	(12)
Loss on disposal of property and equipment			2	5
Share-based compensation	1,067	1,097	1,394	1,752
Changes in assets and liabilities:
Prepaid expenses and other assets	(274)	549	672	13
Other payables and accrued liabilities	(176)	(738)	(683)	(241)
Insurance recovery related to legal settlement and legal expenses received in cash	1,335
Legal settlement paid in cash	(1,100)
Net cash flows used in operating activities	(7,136)	(6,712)	(8,533)	(11,549)
Investing activities:
Proceeds from short term deposit		3	3	(3)
Purchases of property and equipment	(18)	(38)	(33)	(84)
Sale of property and equipment		2
Proceeds from maturities of marketable securities	2,500	5,389	9,164
Purchases of marketable securities	(5,120)	(8,379)	(10,060)	(3,749)
Proceeds from sales of marketable securities	2,680	2,039	2,899
Net cash flows provided by (used in) investing activities	42	(984)	1,973	(3,836)
Financing activities:
Issuance of common stock and warrants, net of issuance costs	5,104	6,558	6,558	4,324
Net cash flows provided by financing activities	5,104	6,558	6,558	4,324
Decrease in cash, cash equivalents and restricted cash	(1,990)	(1,138)	(2)	(11,061)
Cash, cash equivalents and restricted cash at beginning of period	2,517	2,519	2,519	13,580
Cash, cash equivalents and restricted cash at end of period	527	1,381	2,517	2,519
Supplemental disclosure of cash flow information:
Cash received from interest	168	100	130	51
Right-of-use assets obtained in exchange for lease liabilities	37	20	$ 50	$ 103
Supplemental disclosure of non-cash investing and financing activities:
Legal settlement settled through issuance of common stock	1,111
Accrued executive bonus settled through grant of stock-option awards	$ 76

GENERAL

GENERAL	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GENERAL	NOTE 1 – GENERAL A. Description of business Microbot Medical Inc. (the “Company”) is a pre-clinical medical device company specializing in the research, design, and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The Company is primarily focused on leveraging its micro-robotic technologies with the goal of redefining surgical robotics while improving surgical outcomes for patients. The Company incorporated on August 2, 1988 On November 28, 2016, the Company consummated a transaction pursuant to an Agreement and Plan of Merger, dated August 15, 2016, with Microbot Medical Ltd., a private medical device company organized under the laws of the State of Israel (“Microbot Israel”). On the same day and in connection with the Merger, the Company changed its name from StemCells, Inc. to Microbot Medical Inc. On November 29, 2016, the Company’s common stock began trading on the Nasdaq Capital Market under the symbol “MBOT”. The Company and its subsidiary are sometimes collectively referred to as the “Company” as the context may require. B. Risk Factors Going Concern To date, the Company has not generated revenues from its operations. As of September 30, 2024, the Company had cash equivalents and a marketable securities balance of approximately $ 4,338 Accordingly, these conditions raise substantial doubt about the Company’s ability to continue as a going concern. War in Israel On October 7, 2023, the State of Israel, where the Company’s operations are primarily based, suffered a surprise attack by hostile forces from Gaza, which led to ongoing military operations and armed conflicts in the Gaza Strip. It continues to evolve and has since spread to northern Israel and threatens to spread to other Middle Eastern countries including Lebanon and Iran. These military operations and related activities are on-going as of the issuance date of these financial statements. The Company has considered various ongoing risks relating to the military operation and related matters, including: ● That some of the Company’s Israeli subcontractors, vendors, suppliers and other companies in which the Company relies, are currently only partially active, as instructed by the relevant authorities; ● A slowdown in the number of international flights in and out of Israel; and ● Reduced workforce due to military service of some employees The Company is closely monitoring how the military operation and related activities could adversely affect its anticipated milestones and its Israel-based activities to support future clinical and regulatory milestones, including the Company’s ability to import materials that are required to construct the Company’s devices and to ship them outside of Israel. As of the filing date of the Quarterly Report on Form 10-Q of which these financial statements are a part, the Company has determined that there have not been any materially adverse effects on its business or operations, but it continues to monitor the situation, as any future escalation or change could result in a material adverse effect on the ability of the Company’s Israeli office to support the Company’s clinical and regulatory activities. The Company does not have any specific contingency plans in the event of any such escalation or change. C. Unaudited Interim Condensed Financial Statements The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim condensed financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission (“SEC”) regulations. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). These interim condensed consolidated financial statements should be read in conjunction with the latest audited financial statements. Operating results for the nine-month period ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.	NOTE 1 – GENERAL A. Description of business: Microbot Medical Inc. (the “Company”) is a preclinical medical device company specializing in the research, design and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The Company is primarily focused on leveraging its micro-robotic technologies with the goal of redefining surgical robotics while improving surgical outcomes for patients. The Company incorporated on August 2, 1988 On November 28, 2016, the Company consummated a transaction pursuant to an Agreement and Plan of Merger, dated August 15, 2016, with Microbot Medical Ltd., a private medical device company organized under the laws of the State of Israel (“Microbot Israel”). On the same day and in connection with the Merger, the Company changed its name from StemCells, Inc. to Microbot Medical Inc. On November 29, 2016, the Company’s common stock began trading on the Nasdaq Capital Market under the symbol “MBOT”. The Company and its subsidiary are sometimes collectively referred to as the “Company” as the context may require. B. Risk Factors: Going Concern To date, the Company has not generated revenues from its operations. As of December 31, 2023, the Company had cash equivalents and marketable securities balance of approximately $ 6,385 , excluding restricted cash. Due to continuing research and development activities, the Company expects to continue to incur additional losses for the foreseeable future. The Company implemented a cost reduction program in May 2023, and consummated capital raises in May and June 2023 and in January 2024. The Company will seek to raise additional funds through future issuances of either debt and/or equity securities and possibly additional grants from the Israeli Innovation Authority and other government institutions. The Company’s ability to raise additional capital in the equity and debt markets is dependent on a number of factors, including, but not limited to, the market demand for the Company’s stock, which itself is subject to a number of development and business risks and uncertainties, as well as the uncertainty that the Company would be able to raise such additional capital at a price or on terms that are favorable to the Company. Accordingly, these conditions raise substantial doubt about the Company’s ability to continue as a going concern. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) B. Risk Factors: War in Israel On October 7, 2023, the State of Israel, where the Company’s operations are primarily based, suffered a surprise attack by hostile forces from Gaza, which led to the declaration by Israel of the “Iron Swords” military operation. This military operation and related activities are on-going as of the issuance date of these financial statements. The Company has considered various ongoing risks relating to the military operation and related matters, including: ● That some of the Company’s Israeli subcontractors, vendors, suppliers and other companies in which the Company relies, are currently only partially active, as instructed by the relevant authorities; and ● A slowdown in the number of international flights in and out of Israel. The Company is closely monitoring how the military operation and related activities could adversely affect its anticipated milestones and its Israel-based activities to support future clinical and regulatory milestones, including the Company’s ability to import materials that are required to construct the Company’s devices and to ship them outside of Israel. As of the issuance date of these financial statements, the Company has determined that there have not been any materially adverse effects on its business or operations, but it continues to monitor the situation, as any future escalation or change could result in a material adverse effect on the ability of the Company’s Israeli office to support the Company’s clinical and regulatory activities. The Company does not have any specific contingency plans in the event of any such escalation or change.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The significant accounting policies followed in the preparation of these unaudited interim condensed consolidated financial statements are identical to those applied in the preparation of the Company’s latest annual audited financial statements, except if noted below. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions pertaining to transactions and matters whose ultimate effect on the financial statements cannot precisely be determined at the time of financial statements preparation. Although these estimates are based on management’s best judgment, actual results may differ from these estimates. Fair value of financial instruments The carrying values of cash and cash equivalents, other receivables and other accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of these instruments. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories: Level 1 Level 2 Level 3 The following tables summarizes the Company’s financial assets subject to fair value measurement and the level of inputs used in such measurements as of September 30, 2024 and December 31, 2023: SCHEDULE OF FINANCIAL ASSETS FAIR VALUE MEASUREMENT As of September 30, 2024 Total Level 1 Level 2 Level 3 Money market mutual funds $ 3,859 $ 3,859 $ - $ - As of December 31, 2023 Total Level 1 Level 2 Level 3 Marketable securities: U.S. treasury securities $ 2,497 $ 2,497 $ - $ - Money market mutual funds 1,420 1,420 - - $ 3,917 $ 3,917 $ - $ - The Company’s financial assets are measured at fair value on a recurring basis by level within the fair value hierarchy. The Company’s securities and money market funds are classified as Level 1. Other than that, the Company doesn’t have any other financial assets or financial liabilities marked to market at fair value as of September 30, 2024 and December 31, 2023. Share-based compensation The Company applies ASC 718-10, “Share-Based Payment” (“ASC 718-10”), which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors including stock options under the Company’s stock plans based on estimated fair values. ASC 718-10 requires companies to estimate the fair value of stock options using an option-pricing model, which is recognized as an expense over the requisite service periods in the Company’s statement of comprehensive loss, based on a straight-line method. The Company recognizes compensation cost for an equity classified award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant date fair value of such award that is vested at that date. The Company recognizes the expense for an equity classified awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. If no explicit service period is determined, the Company estimates the implicit service period based on the timing the employee is expected to achieve the related performance condition. When no future services are required to be performed by the grantee in exchange for an award of equity instruments, and if such award does not contain a performance or market condition, the cost of the award is expensed on the grant date. The Company estimates the fair value of stock options granted as share-based payment awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on the standard deviation of the Company’s closing prices according to the expected life (SAB107) for each of the grants. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected stock option term is calculated for stock options granted using the “simplified” method for awards that qualify as “plain-vanilla” options. Changes in the determination of each of the inputs can affect the fair value of the stock options granted and the results of operations of the Company. Contingencies Management records and discloses legal contingencies in accordance with ASC Topic 450 Contingencies. A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company monitors the stage of progress of its litigation matters to determine if any adjustments are required. The Company carries liability insurance to mitigate its exposure to losses, including litigation losses. The Company records the estimated amount of expected insurance proceeds for litigation losses incurred as an asset (typically a receivable from the insurer) and offset to losses up to the amount of the losses incurred when the amount is determinable and approved by the insurance company. Recently issued accounting pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption. Segment Reporting In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, to update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendment is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements and related disclosures.	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The significant accounting policies applied in the preparation of the financial statements are as follows: A. Basis of presentation The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). B. Financial statement in U.S. dollars The functional currency of the Company is the U.S. dollar (“dollar”) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future. Transactions and balances denominated in dollars are presented at their original amounts. Transactions and balances denominated in foreign currencies have been re-measured to dollars in accordance with the provisions of Accounting Standards Codification (“ASC”) 830-10, “Foreign Currency Translation”. All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statements of comprehensive loss as financial income or expenses, as appropriate. C. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions pertaining to transactions and matters whose ultimate effect on the financial statements cannot precisely be determined at the time of financial statements preparation. Although these estimates are based on management’s best judgment, actual results may differ from these estimates. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES D. Principles of consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. Inter-company balances and transactions have been eliminated in consolidation. E. Reclassification of prior year disclosures: Certain prior year amounts have been reclassified for consistency with the current year disclosures. These reclassifications had no effect on the reported consolidated balance sheets, the related consolidated statements of comprehensive loss, shareholders’ equity and cash flows. F. Acquisitions of assets The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is accounted for as business combination or an acquisition of assets. G. Cash and cash equivalents Cash and cash equivalents consist of cash and demand deposits in banks, and other short-term liquid investments (primarily interest-bearing time deposits) with original maturities of three months or less at the date of purchase. H. Restricted cash Restricted cash of $ 49 77 I. Fair value of financial instruments The carrying values of cash and cash equivalents, other receivable and other accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of these instruments. The Company measures the fair value of certain of its financial instruments (such as marketable securities) on a recurring basis. The method of determining the fair value of marketable securities is discussed in Note 4 below. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories: Level 1 Level 2 Level 3 J. Concentrations of credit risk: Financial instruments which potentially subject the Company to credit risk consist primarily of cash and cash equivalents and marketable securities. The Company holds these investments in highly rated financial institutions. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES K. Property and equipment Property and equipment are presented at cost less accumulated depreciation. Depreciation is calculated based on the straight-line method over the estimated useful lives of the assets, at the following annual rates: SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT % Research equipment and software 25 33 Furniture and office equipment 7 Leasehold improvements Over the lease period The Company assesses property and equipment impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the property and equipment assets, or the appropriate grouping of assets, is compared to the carrying value to determine whether impairment exists. If an asset is determined to be impaired, the loss is measured based on the difference between the asset’s estimated fair value and its carrying value. For property and equipment assets, the estimate of fair value is typically based on a discounted cash flow model. As of December 31, 2023, and 2022, no impairment charge has been recorded. L. Liabilities due to termination of employment agreements Under Israeli employment laws, employees of Microbot Israel are included under Article 14 of the Severance Compensation Act, 1963 (“Article 14”). According to Article 14, these employees are entitled to monthly deposits made by Microbot Israel on their behalf with insurance companies. Payments in accordance with Article 14 release Microbot Israel from any future severance payments (under the Israeli Severance Compensation Act, 1963) with respect of those employees. The aforementioned deposits are not recorded as an asset in the Company’s balance sheets. As for the U.S. employees, the Company has certain defined contribution plans, including a 401(k)-retirement plan in the U.S., whereby contributions made by eligible employees are matched by the Company with certain limitations. M. Common stock warrants The Company accounts for warrants issued to investors as either equity-classified or liability-classified instruments, based on an assessment of the warrant’s specific terms and the applicable authoritative guidance in FASB ASC 480 and FASB ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, or meet all of the requirements for equity classification under FASB ASC 815, including whether the warrants are indexed to the Company’s own shares of common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. N. Basic and diluted net loss per share Basic net loss per share is calculated by dividing net loss attributable to common stock shareholders by the weighted average number of shares of common stock outstanding during the year without consideration of potentially dilutive securities. For purposes of the diluted net loss per share attributable to common shareholders calculation, stock options and warrants are considered to be common stock equivalents. All common stock equivalents have been excluded from the calculation of the diluted loss per share for the years ended December 31, 2023 and December 31, 2022, as their effect would be anti-dilutive. Therefore, basic and diluted net loss per share were the same for both years presented. In the calculation of the basic and diluted net loss, the Company included warrants that would be exercised for no or little consideration and are exercisable with no contingencies. O. General and administrative expenses, net: General and administrative expenses are charged to the statement of comprehensive loss as incurred. Insurance loss recoveries are recognized when the amount is determinable and approved by the insurance company and applied as a deduction from general and administrative expenses. General and administrative expenses, net, for the years ended December 31, 2023 and 2022, were offset by insurance loss recoveries in the amounts of approximately $ 281 156 P. Research and development expenses, net: Research and development expenses are charged to the statement of comprehensive loss as incurred. Grants for funding of approved research and development projects and others are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred and applied as a deduction from the research and development expenses. See Note 2V below. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Q. Share-based compensation The Company applies ASC 718-10, “Share-Based Payment” (“ASC 718-10”), which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors including stock options under the Company’s stock plans based on estimated fair values. ASC 718-10 requires companies to estimate the fair value of stock options using an option-pricing model, which is recognized as an expense over the requisite service periods in the Company’s statement of comprehensive loss, based on a straight-line method. The Company recognizes compensation cost for an equity classified award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant date fair value of such award that is vested at that date. The Company estimates the fair value of stock options granted as share-based payment awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on the standard deviation of the Company’s closing prices according to the expected life (SAB107) for each of the grants. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected stock option term is calculated for stock options granted using the “simplified” method. Changes in the determination of each of the inputs can affect the fair value of the stock options granted and the results of operations of the Company. R. Income taxes The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2023, and 2022, the Company had a full valuation allowance against deferred tax assets. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES S. Marketable securities The Company invests in various debt securities and an equity security. Debt securities consist of U.S. treasury securities. Equity security consist of a mutual fund. The Company records these investments in the consolidated balance sheet at fair value. For all of the Company’s debt securities, the Company elected the fair value option and thus all unrealized gains or losses for these securities are reflected in the statements of comprehensive loss as financial income or expenses, as appropriate. Unrealized gains or losses for the equity security are reflected in the statements of comprehensive loss as financial income or expenses, as appropriate. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations. T. Leases: The Company determines if an arrangement is a lease at inception. Operating lease assets are presented as operating lease long-term right-of-use assets (“ROU”), and corresponding as lease liabilities (current portion), and as operating long-term lease liabilities, on the Company’s consolidated balance sheets. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the remaining lease payments over the lease term at commencement date. The Company’s leases do not provide an implicit interest rate. The Company calculates the incremental borrowing rate to reflect the interest rate that it would have to pay to borrow on a collateralized basis an amount equal to the lease payments in a similar economic environment over a similar term and considers the Company’s historical borrowing activities and market data in this determination. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that it will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which it accounts for as a single lease component. The Company has elected not to recognize ROU assets and lease liabilities for short-term leases that have a term of 12 months or less. The effect of short-term leases on the Company’s ROU assets and lease liabilities was not material. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. In addition, the Company does not have any related party leases. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES U. Contingencies: Management records and discloses legal contingencies in accordance with ASC Topic 450 Contingencies. A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company monitors the stage of progress of its litigation matters to determine if any adjustments are required. Refer to Note 16C below. The Company carries liability insurance to mitigate its exposure to losses, including litigation losses. The Company records the estimated amount of expected insurance proceeds for litigation losses incurred as an asset (typically a receivable from the insurer) and offset to losses up to the amount of the losses incurred when the amount is determinable and approved by the insurance company. Refer to Note 2O above and Note 16C below. V Government grants: Government grants which are received from the Israeli Ministry of Economy and Israel Innovation Authority (“IIA”) by way of participation in research and development that is conducted by Microbot Israel, are received in installments as the program progresses based on qualified research spending. Grants received are recognized when the grant becomes receivable, provided there was reasonable assurance that Microbot Israel will comply with the conditions attached to the grant and there was reasonable assurance the grant will be received. The grants are deducted from the research and development expenses as the applicable costs are incurred. Research and development expenses, net, for the years ended December 31, 2023 and 2022, include participation in research and development expenses in the amount of approximately $ 279 0 W. Recently issued accounting pronouncements: From time to time, new accounting pronouncements are issued by FASB, or other standard-setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.

CASH AND CASH EQUIVALENTS AND M

CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES	12 Months Ended
	Dec. 31, 2023
Cash and Cash Equivalents [Abstract]
CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES	NOTE 3 – CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES The following table sets forth our cash, cash equivalents and marketable securities as of December 31, 2023 and 2022: SCHEDULE OF CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES As of December 31, 2023 2022 Cash and cash equivalents: Cash $ 2,468 $ 1,195 U.S. treasury securities - 1,247 Total cash and cash equivalents $ 2,468 $ 2,442 Marketable securities: Money market mutual funds $ 1,420 $ 1,999 U.S. treasury securities 2,497 3,761 Total marketable securities $ 3,917 $ 5,760 Total cash, cash equivalents and marketable securities $ 6,385 $ 8,202 The unrealized gains on our marketable securities were $ 59 12 Treasuries have contractual maturities of less than 12 months. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data)

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2023
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 4 - FAIR VALUE MEASUREMENTS The following table summarizes the Company’s financial assets subject to fair value measurement and the level of inputs used in such measurements as of December 31, 2023 and 2022: SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES As of December 31, 2023 Total Level 1 Level 2 Level 3 Marketable securities: U.S. treasury securities $ 2,497 $ 2,497 $ - $ - Money market mutual funds 1,420 1,420 - - $ 3,917 $ 3,917 $ - $ - As of December 31, 2022 Total Level 1 Level 2 Level 3 Cash equivalents: U.S. treasury securities $ 1,247 $ 1,247 $ - $ - Marketable securities: U.S. treasury securities $ 3,761 $ 3,761 $ - $ - Money market mutual funds 1,999 1,999 - - $ 5,760 $ 5,760 $ - $ - The Company’s financial assets are measured at fair value on a recurring basis by level within the fair value hierarchy. The Company’s securities and money market funds are classified as Level 1. Other than that, the Company doesn’t have any other financial assets or financial liabilities marked to market at fair value as of December 31, 2023 and 2022.

PREPAID EXPENSES AND OTHER CURR

PREPAID EXPENSES AND OTHER CURRENT ASSETS	12 Months Ended
	Dec. 31, 2023
Prepaid Expenses And Other Current Assets
PREPAID EXPENSES AND OTHER CURRENT ASSETS	NOTE 5 – PREPAID EXPENSES AND OTHER CURRENT ASSETS SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS As of December 31, 2023 2022 Amounts due from government institutions $ 61 $ 103 Prepaid expenses and other receivables 91 429 Total prepaid expenses and other current assets $ 152 $ 532 MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data)

LEASES

LEASES	12 Months Ended
	Dec. 31, 2023
Leases [Abstract]
LEASES	NOTE 6 - LEASES In November 2019, the Company signed an office space lease agreement for the period from November 2019 until October 2024. In addition, the Company received an option to extend the lease agreement for an additional 5 years. 16 . 49 The following table presents the components of the Company’s lease cost and the classification of such costs in the Company’s consolidated statements of comprehensive loss for the years ended December 31, 2023 and 2022: SCHEDULE OF STATEMENTS OF COMPREHENSIVE LOSS Component of Lease Cost Statements of Comprehensive Loss Line Item 2023 2022 For the Years Ended December 31, Component of Lease Cost Statements of Comprehensive Loss Line Item 2023 2022 Operating lease cost Research and development, net $ 279 $ 300 Supplemental cash flow information related to operating leases was as follows: SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES 2023 2022 For the Years Ended December 31, 2023 2022 Cash paid under operating lease agreements $ 283 $ 344 Undiscounted maturities of future operating lease payments as of December 31, 2023 are summarized as follows: SCHEDULE OF MATURITIES OF LEASE LIABILITIES As of December 31, 2023 2024 $ 208 2025 48 2026 21 Total future lease payments 277 Less imputed interest (47 ) Total lease liabilities $ 231 The following table includes the weighted-average lease terms and discount rates for operating leases as of December 31, 2023 and 2022: SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES As of December 31, 2023 2022 Operating leases weighted average remaining lease term (in years) 0.8 2 Operating leases weighted average discount rate 7 % 9 % MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data)

PROPERTY AND EQUIPMENT, NET

PROPERTY AND EQUIPMENT, NET	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT, NET	NOTE 7 - PROPERTY AND EQUIPMENT, NET SCHEDULE OF PROPERTY AND EQUIPMENT 2023 2022 As of December 31, 2023 2022 Historical Cost: Research equipment and software $ 177 $ 143 Leasehold improvement 229 229 Furniture and office equipment 233 236 Cost 639 608 Accumulated Depreciation: Research equipment and software 109 63 Leasehold improvement 181 135 Furniture and office equipment 203 189 Accumulated Depreciation 493 387 Net book value $ 146 $ 221

ACCRUED LIABILITIES

ACCRUED LIABILITIES	12 Months Ended
	Dec. 31, 2023
Payables and Accruals [Abstract]
ACCRUED LIABILITIES	NOTE 8 - ACCRUED LIABILITIES SCHEDULE OF ACCRUED LIABILITIES As of December 31, 2023 2022 Employee-related liabilities $ 725 $ 1,372 Other current liabilities 302 298 Total Accrued Liabilities $ 1,027 $ 1,670 MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data)

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 3 - COMMITMENTS AND CONTINGENCIES A. Government grants: Microbot Israel has received grants from the Israeli Innovation Authority (“IIA”) for participation in research and development since 2013 through September 30, 2024 totaling approximately $ 1,878 378 1,620,000 447 ® In addition, as a result of the agreement with CardioSert Ltd. (“CardioSert”) on January 4, 2018, Microbot Israel took over the liability to repay CardioSert’s IIA grants in the aggregate amount of approximately $ 530 In addition, as a result of the agreement with Nitiloop, on October 6, 2022, Microbot Israel took over the liability to repay Nitiloop’s IIA grants in the aggregate amount of approximately $ 925 In relation to the IIA grants described above, the Company is obligated to pay royalties amounting to 3.0 5 The grants are linked to the exchange rate of the dollar to the New Israeli Shekel and bears interest of SOFR per year (SOFR is a benchmark interest rate which replaced LIBOR). The repayment of the grants is contingent upon the successful completion of the Company’s research and development programs and generating sales. The Company has no obligation to repay these grants, if the project fails, is unsuccessful or aborted or if no sales are generated. The financial risk is assumed completely by the Government of Israel. The grants are received from the Government on a project-by-project basis. On December 11, 2022, the Company received approval for a grant from the Ministry of Economy, in the amount of NIS 300,000 83 ® 50 3 B. TRDF agreement: Microbot Israel signed an agreement with the Technion Research and Development Foundation (“TRDF”) in June 2012 by which TRDF transferred to Microbot Israel a global, exclusive, royalty-bearing license (as amended, the “License Agreement”) with respect to the Company’s Self-Cleaning Shunt (SCS) project and its TipCat assets in addition to certain technology relating to the Company’s LIBERTY ® 1.5 3.0 In October 2022 the Company suspended the SCS project and as a result of the Company’s May 2023 implementation of its core-business focus program and cost reduction plan, the Company returned the licensed intellectual property for the TipCat back to TRDF in June 2023, and returned the licensed intellectual property for the SCS (ViRob) back to TRDF in July 2023. As a result, as of the date of these financial statements, the License Agreement is limited to the certain technology relating to the Company’s LIBERTY ® C. Agreement with CardioSert Ltd.: On January 4, 2018, Microbot Israel entered into an agreement with CardioSert (the “CardioSert Agreement”) to acquire certain of its patent-protected technology (the “Technology”). Pursuant to the CardioSert Agreement, Microbot Israel made aggregate payments of $ 300 6,738 74 As a result of its core-business focus program and its cost reduction plan enacted in May 2023, the Company terminated the CardioSert Agreement effective as of August 17, 2023 in accordance with its terms and ceased its research and development and commercialization efforts for, and maintaining, the Technology, which resulted in CardioSert triggering on March 3, 2024 its right to reacquire the Technology for nominal consideration. See also Note 5C below. In July 2024, Microbot Israel transferred the Technology back to CardioSert, for nominal consideration, pursuant to the terms of the CardioSert Agreement. As a result, Microbot Israel’s liability to repay CardioSert’s IIA grants in the aggregate amount of approximately $ 530 D. ATM agreement: On June 10, 2021, the Company entered into an At-the-Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co. LLC (“Wainwright”), as sales agent, in connection with an “at the market offering” under which the Company may offer and sell, from time to time in its sole discretion, shares of its common stock having an aggregate offering price of up to $ 10,000 at market prices or as otherwise agreed with Wainwright. The Company entered into an amendment, dated July 1, 2024, to the ATM Agreement with Wainwright dated June 10, 2021, relating to the offer and sale of shares of the Company’s common stock having an aggregate offering price of up to approximately $ 4,820 from time to time through Wainwright, acting as sales agent. The compensation to Wainwright for sales of the shares is a placement fee of 3.0% E. Engagement letters with H.C. Wainwright In connection with registered direct and private placement offerings, the Company entered into engagement letters (the “Engagement Letters”) with Wainwright on October 3, 2022, on May 16, 2023, on October 24, 2023 and on May 29, 2024, pursuant to which Wainwright agreed to serve as the exclusive placement agent for the issuance and sale of securities of the Company. As compensation for such placement agent services, the Company has agreed to pay Wainwright an aggregate cash fee equal to 7.0 1.0 The Company has also agreed to issue to Wainwright or its designees preferred investment options upon the closing of such offerings, equal to five (5.0%) percent of the aggregate number of such shares of common stock in such offerings, including upon exercise for cash of any warrants issued to investors in such offering. F. Acquisition of Nitiloop’s assets: On October 6, 2022, Microbot Israel purchased substantially all of the assets, including intellectual property, devices, components and product related materials (the “Assets”), of Nitiloop Ltd., an Israeli limited liability company (“Nitiloop”). The Assets include intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter (the “Technology”) and the products or potential products incorporating the Technology owned by Nitiloop and designated by Nitiloop as “NovaCross”, “NovaCross Xtreme” and “NovaCross BTK” and any enhancements, modifications and improvements thereof (“Devices”). Microbot Israel did not assume any material liabilities of Nitiloop other than obligations Nitiloop has to the IIA and relating to certain renewal/maintenance fees for a European patent application. In consideration for the acquisition of the Assets, Microbot Israel shall pay royalties to Nitiloop, which shall not, in the aggregate, exceed $ 8,000 Royalties at a rate of 3 Royalties at a rate of 1.5 Based on the Company’s analysis, the Company concluded that the acquisition of the assets does not meet the definition of a business for the purpose of applying SEC Rules (S-X Rules of 3-05, 8-04 and 11-01). G. Litigation resulting from the 2017 financing: The Company was named as the defendant in a lawsuit captioned Empery Asset Master Ltd., Empery Tax Efficient, LP, Empery Tax Efficient II, LP, Hudson Bay Master Fund Ltd., (the “Plaintiffs”), against Microbot Medical Inc., Defendant, in the Supreme Court of the State of New York, County of New York (Index No. 651182/2020) (the “Lawsuit”). The complaint alleged, among other things, that the Company breached multiple representations and warranties contained in the Securities Purchase Agreement (the “SPA”) related to the Company’s June 8, 2017 equity financing (the “2017 Financing”), of which the Plaintiffs participated, and fraudulently induced Plaintiffs into signing the SPA. The complaint sought rescission of the SPA and return of the Plaintiffs’ $ 6,750 On January 26, 2024 (the “Effective Date”), the Company entered into a settlement agreement and release with the Plaintiffs (the “Settlement Agreement”), effectively resolving the Lawsuit. Pursuant to the Settlement Agreement, the Company paid $ 2,154 1,100 1,005,965 The Company concluded the Settlement Agreement gave rise to loss contingencies in the scope of ASC Subtopic 450-20, Contingencies – Loss Contingencies, and as of December 31, 2023, the Company recorded a contingent liability, as the Company deemed it both probable and reasonably estimable. The Company determined that the loss contingency should be recognized as non-operating losses, offset by loss recoveries received from the Company’s insurance company. As a result of the Settlement Agreement and the insurance recovery received from the insurance company, as of December 31, 2023, the Company recorded a liability and an asset on its balance sheet totaling $ 2,211 1,335 1,100 235 1,111 1,335 1,100 1,005,965 H. Mona litigation: On April 28, 2019, the Company brought an action against Alliance Investment Management, Ltd. (“Alliance”), later amended to add Joseph Mona (“Mona”) as a defendant, in the Southern District of New York under Section 16(b) of the Securities Exchange Act of 1934 (the “Exchange Act”), to compel Alliance and/or Mona to disgorge short swing profits realized from purchases and sales of the Company’s securities within a period of less than six months. The amount of profits was estimated in the complaint to be approximately $ 468 On March 31, 2021, the Court entered a judgment against Mona and in favor of the Company in the amount of approximately $ 485 On August 22, 2023, the District Court dismissed the Section 10(b) counterclaim in its entirety. After the Company initiated efforts to execute on the $ 485 As of May 10, 2024, Mona posted a bond in the full amount of the Judgment, which the Company will move to collect if the appeal is denied or the original judgment in the Company’s favor is upheld. I. Contingent bonus commitments based on future capital raising: In February 2024, the Compensation Committee of the Board of Directors of the Company approved certain bonuses for the 2023 fiscal year contingent on capital raising efforts. These bonuses are detailed as follows: The Company’s CEO was granted a contingent cash bonus of up to approximately $ 298 50% 149 3,000 3,000 50% 149 The remaining 50% 149 6,000 3,000 6,000 10,000 Other executives are entitled to an aggregate contingent total bonus of NIS 230,736 61 3,000 3,000 61	NOTE 9 - COMMITMENTS AND CONTINGENCIES A. Government grants: Microbot Israel has received grants from the IIA for participation in research and development since 2013 through December 31, 2023 totaling approximately $ 1,804 . This amount includes amounts received in 2023 of approximately $ 304 , which are a portion of an additional grant from the IIA in the amount of approximately NIS 1,620,000 (approximately $ 447 ) approved by the IIA on June 1, 2023, to further finance the development of the manufacturing process of the LIBERTY ® In addition, as a result of the agreement with CardioSert Ltd. (“CardioSert”) on January 4, 2018, Microbot Israel took over the liability to repay CardioSert’s IIA grants in the aggregate amount of approximately $ 530 In addition, as a result of the agreement with Nitiloop, on October 6, 2022, Microbot Israel took over the liability to repay Nitiloop’s IIA grants in the aggregate amount of approximately $ 925 In relation to the IIA grants described above, the Company is obligated to pay royalties amounting to 3.0% 5 The grants are linked to the exchange rate of the dollar to the New Israeli Shekel and bears interest of SOFR per year (SOFR is a benchmark interest rate which replaced LIBOR). The repayment of the grants is contingent upon the successful completion of the Company’s research and development programs and generating sales. The Company has no obligation to repay these grants, if the project fails, is unsuccessful or aborted or if no sales are generated. The financial risk is assumed completely by the Government of Israel. The grants are received from the Government on a project-by-project basis. On December 11, 2022, the Company received approval for a grant from the Ministry of Economy, in the amount of NIS 300,000 (approximately $ 83 ), for participation in expenses related to the LIBERTY ® 27 of such grant. In relation with the Ministry of Economy grant, the Company is obligated to pay royalties amounting to 3% of future sales of the LIBERTY ® B. TRDF agreement: Microbot Israel signed an agreement with the Technion Research and Development Foundation (“TRDF”) in June 2012 by which TRDF transferred to Microbot Israel a global, exclusive, royalty-bearing license (as amended, the “License Agreement”) with respect to the Company’s Self-Cleaning Shunt (SCS) project and its TipCat assets in addition to certain technology relating to the Company’s LIBERTY ® 1.5% - 3.0% ) and on sublicense income as detailed in the License Agreement. In October 2022 the Company suspended the SCS project and as a result of the Company’s May 2023 implementation of its core-business focus program and cost reduction plan, the Company returned the licensed intellectual property for the TipCat back to TRDF in June 2023, and returned the licensed intellectual property for the SCS (ViRob) back to TRDF in July 2023. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 9 - COMMITMENTS AND CONTINGENCIES C. Agreement with CardioSert Ltd.: On January 4, 2018, Microbot Israel entered into an agreement with CardioSert (the “CardioSert Agreement”) to acquire certain of its patent-protected technology (the “Technology”). Pursuant to the CardioSert Agreement, Microbot Israel made aggregate payments of $ 300 6,738 74 The CardioSert Agreement may be terminated by CardioSert in case the first commercial sale does not occur by the third anniversary of the date of signing of the CardioSert Agreement except if Microbot Israel has invested more than $ 2,000 In each of the above termination events, or in case of breach by Microbot Israel, CardioSert shall have the right to buy back the Technology from Microbot Israel for $ 1.00 (dollar not in thousands), upon 60 days prior written notice, but only 1 year after such termination events. Additionally, the CardioSert Agreement may be terminated by either party upon breach of the other (subject to cure). Until May 2023, Microbot Israel paid CardioSert a monthly consultation fee of NIS 40,000 (or approximately US$ 11 , based on an exchange rate of NIS 3.7 to the dollar) covering up to 60 consulting hours per month, relating to the development of the Technology . As a result of its core-business focus program and its cost reduction plan enacted in May 2023, the Company has terminated the CardioSert Agreement effective as of August 17, 2023 and ceased its research and development and commercialization efforts for, and maintaining, the Technology, which subsequent to the balance sheet date resulted in CardioSert triggering its right to reacquire the Technology for nominal consideration. See Note 16E below. D. ATM agreement: On June 10, 2021, the Company entered into an At-the-Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co. LLC (“Wainwright”), as sales agent, in connection with an “at the market offering” under which the Company may offer and sell, from time to time in its sole discretion, shares of its common stock having an aggregate offering price of up to $ 10,000 MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 9 - COMMITMENTS AND CONTINGENCIES E. Engagement letters with H.C. Wainwright: In connection with registered direct and private placement offerings referred to in Note 10 below, the Company entered into engagement letters (the “Engagement Letters”) with Wainwright on October 3, 2022, on May 16, 2023 and on October 24, 2023, pursuant to which Wainwright agreed to serve as the exclusive placement agent for the issuance and sale of securities of the Company. As compensation for such placement agent services, the Company has agreed to pay Wainwright an aggregate cash fee equal to 7.0% of the gross proceeds received by the Company from offerings contemplated by the Engagement Letters, plus a management fee equal to 1.0% of the gross proceeds received by the Company from such offerings, as well as other reimbursable expenses. The Company has also agreed to issue to Wainwright or its designees preferred investment options upon the closing of such offerings, equal to five (5.0%) percent of the aggregate number of such shares of common stock in such offerings, including upon exercise for cash of any warrants issued to investors in such offering. F. Acquisition of Nitiloop’s assets: On October 6, 2022, Microbot Israel purchased substantially all of the assets, including intellectual property, devices, components and product related materials (the “Assets”), of Nitiloop Ltd., an Israeli limited liability company (“Nitiloop”). The Assets include intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter (the “Technology”) and the products or potential products incorporating the Technology owned by Nitiloop and designated by Nitiloop as “NovaCross”, “NovaCross Xtreme” and “NovaCross BTK” and any enhancements, modifications and improvements thereof (“Devices”). Microbot Israel did not assume any material liabilities of Nitiloop other than obligations Nitiloop has to the IIA and relating to certain renewal/maintenance fees for a European patent application. In consideration for the acquisition of the Assets, Microbot Israel shall pay royalties to Nitiloop, which shall not, in the aggregate, exceed $ 8,000 ● Royalties at a rate of 3% ● Royalties at a rate of 1.5% Based on the Company’s analysis, the Company concluded that the acquisition of the assets does not meet the definition of a business for the purpose of applying SEC Rules (S-X Rules of 3-05, 8-04 and 11-01). MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 9 - COMMITMENTS AND CONTINGENCIES G. Litigation resulting from the 2017 financing: The Company was named as the defendant in a lawsuit captioned Empery Asset Master Ltd., Empery Tax Efficient, LP, Empery Tax Efficient II, LP, Hudson Bay Master Fund Ltd., (the “Plaintiffs”), against Microbot Medical Inc., Defendant, in the Supreme Court of the State of New York, County of New York (Index No. 651182/2020) (the “Lawsuit”). The complaint alleged, among other things, that the Company breached multiple representations and warranties contained in the Securities Purchase Agreement (the “SPA”) related to the Company’s June 8, 2017 equity financing (the “2017 Financing”), of which the Plaintiffs participated, and fraudulently induced Plaintiffs into signing the SPA. The complaint sought rescission of the SPA and return of the Plaintiffs’ $ 6,750 The Lawsuit was settled in January 2024. Refer to Note 16C below. H. Mona litigation : On April 28, 2019, the Company brought an action against Alliance Investment Management, Ltd. (“Alliance”), later amended to add Joseph Mona (“Mona”) as a defendant, in the Southern District of New York under Section 16(b) of the Securities Exchange Act of 1934 (the “Exchange Act”), to compel Alliance and/or Mona to disgorge short swing profits realized from purchases and sales of the Company’s securities within a period of less than six months. The amount of profits was estimated in the complaint to be approximately $ 468 On March 31, 2021, the Court entered a judgment against Mona and in favor of the Company in the amount of approximately $ 485 On August 4, 2023, the Magistrate Judge issued a Report & Recommendation, which recommended that the District Court dismiss Mona’s Section 10(b) counterclaim in the entirety. On August 22, 2023, the District Court adopted the Report and Recommendation in full and dismissed the Section 10(b) counterclaim in its entirety. The time for appeal has expired and the Company is proceeding with collection efforts for the $ 485 The Court has permitted the Company’s ongoing execution efforts to continue notwithstanding Mona’s purported appeal of the Court’s denial of his motion to vacate. On March 15, 2024, the Magistrate Judge issued an Order to Show Cause (“OTSC”) directing the liquidation of certain of Mona’s accounts, and the transfer of the sale proceeds to the Company in partial satisfaction of the Judgment. The OTSC hearing is scheduled to be held in the second quarter of 2024. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data)

SHARE CAPITAL

SHARE CAPITAL	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Equity [Abstract]
SHARE CAPITAL	NOTE 4 - SHARE CAPITAL A. Preferred investment options inducement On December 29, 2023, the Company entered into a preferred investment option exercise inducement offer letter with certain holders of existing (i) Series A preferred investment options to purchase 1,022,495 2.20 350,878 2.075 312,309 3.19 1,685,682 1.62 1,685,682 1.50 2,730 333 84,284 2.025 B. June 2024 Offerings On June 3, 2024, the Company entered into Securities Purchase Agreements with institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of The Nasdaq Stock Market, an aggregate of 1,566,669 0.01 1.50 2,350 328 3,133,338 1.50 The Company also issued to Wainwright or its designees preferred investment options to purchase up to 78,333 1.875 C. Equity component of settlement amount As part of the Settlement Agreement (refer to Note 3G above), the Company issued 1,005,965 D. At-the-market offerings In connection with entering into the ATM Agreement, on July 1, 2024, the Company filed with the SEC a prospectus supplement relating to the offer, issuance and sale of up to $ 4,820 685,800 734 49 E. Equity classification The shares of common stock of the Company are recognized as equity under the requirements of ASC Topic 505 Equity. The Company analyzed the accounting treatment for the series E and series F preferred investment options and concluded that they should be classified as equity. The Company analyzed the accounting treatment for the preferred investment options issued to Wainwright. Since the Company did not identify any features causing liability classification according to ASC 718, it concluded that all such preferred investment options are equity-classified awards. F. Employee and advisor stock option grants In February 2024, the Company granted the CEO, certain executives and certain employees, fully vested options to purchase an aggregate of 130,000 1.2684 The Company also granted the CEO and other executives, options to purchase an aggregate of 132,500 1.25 In February 2024, the Company granted the CEO and certain employees and advisors, options to purchase an aggregate of 195,000 1.2684 three years 25 99 79,567 1.25 In September 2024, the Company granted an advisor options to purchase an aggregate of 25,000 0.8558 three years	NOTE 10 - SHARE CAPITAL A. Share capital developments: As of December 31, 2023 and 2022, the Company has 11,707,317 7,890,628 On October 21, 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an institutional investor (the “Investor”), pursuant to which the Company issued and sold, in a registered direct offering priced at-the-market under the rules of The Nasdaq Stock Market (the “Registered Offering”), (i) an aggregate of 782,495 4.89 240,000 4.8899 5,000 Each Pre-Funded Warrant represents the right to purchase one share of common stock at an exercise price of $ 0.0001 In a concurrent private placement (the “Private Placement” and, together with the Registered Offering, the “Offerings”), the Company issued to the Investor (i) Series A preferred investment options to purchase up to 1,022,495 4.64 1,022,495 4.64 MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 10 - SHARE CAPITAL On October 3, 2022 and in connection with the Offerings, the Company entered into an Engagement Letter with Wainwright as mentioned in Note 9E, as compensation for such placement agent services, the Company paid Wainwright aggregate cash fees and reimbursed Wainwright for its expenses aggregating approximately $ 565 . The Company incurred other related offering expenses of $ 111 51,125 shares of common stock (the “Wainwright Warrants”). The Wainwright Warrants have a term of five years from the commencement of sales in the Offerings, and have an exercise price of $ 6.11 per share. The Company estimated the fair value of the warrants using a Black-Scholes options pricing model and concluded it is approximately $ 138 . On February 13, 2023, 240,000 0.0001 B. Registered direct and private placement offerings: On May 22, 2023, the Company entered into a securities purchase agreement with an institutional investor, pursuant to which it agreed to issue and sell in a registered direct offering an aggregate of 655,569 2.20 1,442 222 32,778 2.75 46 On May 23, 2023, the Company entered into a securities purchase agreement with an institutional investor, pursuant to which it agreed to issue and sell in a registered direct offering (i) an aggregate of 975,000 2.20 234,500 2.1999 2,661 345 0.0001 The Company also issued to Wainwright or its designees preferred investment options to purchase 60,476 2.75 72 MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 10 - SHARE CAPITAL Registered Direct and Private Placement Offerings: On June 2, 2023, the Company entered into a securities purchase agreement with institutional investors, pursuant to which it agreed to issue and sell in a registered direct offering an aggregate of 701,756 shares of common stock, at an offering price of $ 2.1375 per share, for aggregate gross proceeds, with the concurrent private placement described below, of $ 1,500 before deducting the placement agent fee and related offering expenses of approximately $ 227 (the “First June Offering”). The Company also issued to Wainwright or its designees preferred investment options to purchase 35,088 shares of its common stock, which have a term of five years from the commencement of sales in the First June Offering, and have an exercise price of $ 2.6719 per share. The Company estimated the fair value of the warrants using a Black-Scholes options pricing model and concluded it is approximately $ 58 . The registered direct offering was consummated on June 6, 2023. In a concurrent private placement, the Company also issued to the purchasers of shares of common stock in the First June Offering, series C preferred investment options to purchase up to 350,878 shares of common stock. Each series C preferred investment option is exercisable for one share of common stock at an exercise price of $ 2.075 commencing on the date of issuance and expiring five and one-half years from the issuance date. On June 26, 2023, the Company entered into a securities purchase agreement with institutional investors, pursuant to which it agreed to issue and sell in a registered direct offering an aggregate of 624,618 shares of its common stock, at an offering price of $ 3.25 per share, for aggregate gross proceeds, with the concurrent private placement described below, of $ 2,030 before deducting the placement agent fee and related offering expenses of approximately $ 281 (the “Second June Offering”). The Company also issued to Wainwright or its designees preferred investment options to purchase 31,231 shares of its common stock, which have a term of five years from the commencement of sales in the Second June Offering, and have an exercise price of $ 4.0625 per share. The Company estimated the fair value of the warrants using a Black-Scholes options pricing model and concluded it is approximately $ 68 . The registered direct offering was consummated on June 28, 2023. In a concurrent private placement, the Company also issued to the purchasers of shares of common stock in the Second June Offering, series D preferred investment options to purchase up to 312,309 shares of the Company’s common stock. Each series D preferred investment option is exercisable for one share of common stock at an exercise price of $ 3.19 commencing on the date of issuance and expiring five and one-half years from the issuance date. The common stock of the Company are recognized as equity under the requirements of ASC Topic 505 Equity. The Company analyzed the accounting treatment for the series A preferred investment option, the series B preferred investment option, the series C preferred investment option, the series D preferred investment option, and all of the pre-funded warrants issued to investors. Based on the Company’s analysis all such warrants were classified as equity. The Company analyzed the accounting treatment for all of the preferred investment options issued to Wainwright in the aforementioned offerings. Since the Company did not identify any features causing liability classification according to ASC 718, it concluded that all such preferred investment options are equity-classified awards. C. Preferred investment options amendment: In connection with the Second May Offering, the Company amended the terms of (i) the Series A preferred investment options to purchase 1,022,495 4.64 October 25, 2027 1,022,495 4.64 October 25, 2024 2.20 October 25, 2027 1,230 385,246 The grant date fair values of preferred investment options issued to Wainwright and preferred investment options issued to investors that were modified in the years ended December 31, 2023 and 2022 were estimated using the Black-Scholes valuation model with the following: SCHEDULE OF GRANT DATE FAIR VALUE OF PREFERRED INVESTMENT OPTIONS ISSUED TO INVESTORS For the Years Ended December 31, 2023 2022 Expected volatility 101.31 122.39 87.96 % Risk-free interest 3.85 4.93 4.25 % Dividend yield - - Expected terms (years) 1.42 5 4.99 MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 10 - SHARE CAPITAL D. Employee stock option grants: During the year ended December 31, 2022, the Company granted to Mr. Harel Gadot, the Company’s Chairman of the Board, President and CEO (the “CEO”), options to purchase an aggregate of 260,000 3.73 6.48 three years During the year ended December 31, 2022, the Company granted to certain employees, consultants and directors, options to purchase an aggregate of 270,822 3.73 6.48 three years During the year ended December 31, 2023, the Company granted to the CEO, options to purchase an aggregate of 80,000 2.43 three years During the year ended December 31, 2023, the Company granted stock option awards to certain officers, directors and employees to purchase an aggregate of 631,308 1.16 3.48 three years A summary of the Company’s option activity related to options to employees and directors, and related information is as follows: MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 10 - SHARE CAPITAL Employee stock option grants: SUMMARY OF STOCK OPTION ACTIVITY For the Year Ended December 31, 2023 Number of stock options Weighted average exercise price Outstanding as of December 31, 2022 1,507,137 $ 7.31 Granted 711,308 1.75 Forfeitures (123,083 ) 5.78 Outstanding as of December 31, 2023 2,095,362 $ 5.51 Vested as of December 31, 2023 1,176,118 $ 7.74 For the Year Ended December 31, 2022 Number of stock options Weighted average exercise price Outstanding as of December 31, 2021 997,148 $ 8.48 Granted 530,822 5.14 Forfeitures (20,833 ) 8.16 Outstanding as of December 31, 2022 1,507,137 $ 7.31 Vested as of December 31, 2022 899,609 $ 8.52 The Company recognizes forfeitures of outstanding options as they occur. The intrinsic value is calculated as the difference between the fair market value of the common stock and the exercise price, multiplied by the number of in-the-money stock options on those dates that would have been received by the stock option holders had all stock option holders exercised their stock options on those dates as of December 31, 2023 and December 31, 2022, respectively. As of December 31, 2023, and 2022, the aggregate intrinsic value of the outstanding options is $ 277 185 102 185 The weighted average grant date fair value of options granted during the years ended December 31, 2023 and 2022 was $ 1.40 4.5 MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 10 - SHARE CAPITAL Employee stock option grants: As of December 31, 2023, there were approximately $ 1,918 2.4 The stock options outstanding as of December 31, 2023 and December 31, 2022, summarized by exercise prices, are as follows: SCHEDULE OF STOCK OPTIONS OUTSTANDING Exercise price $ Stock options outstanding as of December 31, 2023 Stock options outstanding as of December 31, 2022 Weighted average remaining contractual life – years as of December 31, 2023 Weighted average remaining contractual life – years as of December 31, 2022 Stock options exercisable as of December 31, 2023 Stock options exercisable as of December 31, 2022 0.00 0.01 61,577 61,577 2.3 3.3 61,577 61,577 1.00 3.73 860,808 211,000 9.6 10 95,925 - 4.2 7.26 639,232 687,482 6.3 8.0 484,871 315,807 8.16 9.64 380,872 380,872 6.6 7.6 380,872 356,019 15.3 15.75 152,873 166,206 3.7 4.8 152,873 166,206 2,095,362 1,507,137 1,176,118 899,609 MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 10 - SHARE CAPITAL Employee stock option grants: The grant date fair values of employee stock options granted in the years ended December 31, 2023 and 2022 were estimated using the Black-Scholes valuation model with the following: SCHEDULE OF STOCK OPTIONS VALUATION ASSUMPTIONS For the Years Ended December 31, 2023 2022 Expected volatility 86.5% 98.2 111.2% 161.7% Risk-free interest 3.3 4.7% 1.7% 3.7% Dividend yield - - Expected terms (years) 5.8 6.2 E. Warrants: The remaining outstanding warrants and terms as of December 31, 2023 and 2022 are as follows: SCHEDULE OF WARRANTS OUTSTANDING Issuance date Outstanding and exercisable as of December 31, 2023 Outstanding and exercisable as of December 31, 2022 Exercise Price Exercisable Through Series A (2013) - 183 $ 2,754.00 April 9, 2023 Warrant to underwriters December 2019 - 45,643 $ 13.13 June 25, 2023 Warrant to underwriters December 2019 - 47,619 $ 13.13 June 27, 2023 Warrant to underwriters December 2019 - 45,045 $ 13.88 June 30, 2023 Series A October 2022 1,022,495 1,022,495 $ 2.20 October 25, 2027 Series B October 2022 - 1,022,495 $ 2.20 October 25, 2027 Prefunded warrants October 2022 - 240,000 $ (* ) No limit Warrant to underwriters October 2022 51,125 51,125 $ 6.11 October 21, 2027 Warrant to underwriters May 2023 32,778 - $ 2.75 November 23, 2026 Warrant to underwriters May 2023 60,476 - $ 2.75 November 24, 2026 Warrant to underwriters June 2023 35,088 - $ 2.67 June 2, 2028 Warrant series C June 2023 350,878 - $ 2.08 December 6, 2028 Warrant to underwriters June 2023 31,231 - $ 4.06 June 28, 2028 Warrant series D June 2023 312,309 - $ 3.19 December 28, 2028 (*) Less than $0.01. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data)

BASIC AND DILUTED NET LOSS PER

BASIC AND DILUTED NET LOSS PER SHARE	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
BASIC AND DILUTED NET LOSS PER SHARE	NOTE 11 - BASIC AND DILUTED NET LOSS PER SHARE The basic and diluted net loss per share and weighted average number of shares of common stock used in the calculation of basic and diluted net loss per share were presented in the consolidated statements of comprehensive loss for the years ended December 31, 2023 and 2022. In the calculation of the basic and diluted net loss, the Company included warrants that would be exercised for no or little consideration and are exercisable with no contingencies. Due to the net loss to common shareholders in each of the periods presented above, diluted loss per share was computed without consideration to potentially dilutive instruments as their inclusion would have been anti-dilutive. As of December 31, 2023 and 2022, potentially dilutive securities excluded from the diluted loss per share calculation are as follows: SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES EXCLUDED FROM DILUTED LOSS PER SHARE 2023 2022 For the Years Ended December 31, 2023 2022 Series A 2013 - 183 Warrant to underwriters December 2019 - 45,643 Warrant to underwriters December 2019 - 47,619 Warrant to underwriters December 2019 - 45,045 Series A and B warrants October 2022 1,022,495 2,044,990 Warrant to underwriters October 2022 51,125 51,125 Warrant to underwriters May 2023 32,778 - Warrant to underwriters May 2023 60,476 - Warrant to underwriters June 2023 35,088 - Warrant series C June 2023 350,878 - Warrant to underwriters June 2023 31,231 - Warrant series D June 2023 312,309 - Outstanding employee stock options to purchase common stock 2,095,362 1,507,137 Potentially dilutive securities excluded from diluted loss per share 2,095,362 1,507,137 MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data)

RESEARCH AND DEVELOPMENT EXPENS

RESEARCH AND DEVELOPMENT EXPENSES, NET	12 Months Ended
	Dec. 31, 2023
Research and Development [Abstract]
RESEARCH AND DEVELOPMENT EXPENSES, NET	NOTE 12 - RESEARCH AND DEVELOPMENT EXPENSES, NET SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES 2023 2022 For the Years Ended December 31, 2023 2022 Payroll and related expenses $ 2,455 $ 3,558 Share-based compensation 407 387 Professional services 1,842 2,097 Materials 520 559 Patents 157 341 Rent 213 224 Office and maintenance expenses 55 100 Depreciation 106 102 Other 248 368 Less - grants (279 ) - Research and development expense $ 5,724 $ 7,736

GENERAL AND ADMINISTRATIVE EXPE

GENERAL AND ADMINISTRATIVE EXPENSES, NET	12 Months Ended
	Dec. 31, 2023
General And Administrative Expenses Net
GENERAL AND ADMINISTRATIVE EXPENSES, NET	NOTE 13 - GENERAL AND ADMINISTRATIVE EXPENSES, NET SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES 2023 2022 For the Years Ended December 31, 2023 2022 Payroll and related expenses $ 1,223 $ 1,813 Government fees 58 35 Share-based compensation 988 1,365 Professional services 1,204 1,154 Insurance 442 733 Public and investor relations 148 220 Office and maintenance expenses 95 120 Travel 160 180 Other 94 81 Less – insurance loss recoveries (281 ) (156 ) General and administrative expenses $ 4,131 $ 5,545 MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data)

RELATED PARTIES

RELATED PARTIES	12 Months Ended
	Dec. 31, 2023
Related Party Transactions [Abstract]
RELATED PARTIES	NOTE 14 - RELATED PARTIES There were no material related party transactions in each of the years ended December 31, 2023 and 2022 that were outside of the Company’s normal course of business.

TAXES ON INCOME

TAXES ON INCOME	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
TAXES ON INCOME	NOTE 15 - TAXES ON INCOME The Company is subject to U.S. federal tax rate of 21% The Company has not been audited by the Internal Revenue Service since its incorporation. As of December 31, 2023 and 2022, the Company has generated accumulated net operating losses in the U.S. of approximately $ 506,317 502,053 Microbot Israel is subject to Israeli corporate tax rate of 23% As of December 31, 2023 and 2022, Microbot Israel has generated accumulated net operating losses in Israel of approximately $ 41,164 34,688 MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 15 - TAXES ON INCOME The Company is still in its development stage and has not yet generated revenues, therefore, it is more likely than not that sufficient taxable income will not be available for the tax losses to be utilized in the future. Therefore, a valuation allowance was recorded to reduce the deferred tax assets to its recoverable amounts. SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES 2023 2022 As of December 31, 2023 2022 Net operating loss carryforwards $ 115,778 $ 113,393 Operating lease liabilities 53 105 Accrued vacation pay 59 71 Legal settlement accrual 464 - Advance payment from IIA 17 - Total deferred tax assets 116,371 113,569 Less: valuation allowance (116,014 ) (113,455 ) Net deferred tax assets 357 114 Operating leases, right-of-use assets (60 ) (114 ) Grant receivable ( Ministry of Economy) (5 ) - Insurance recovery receivable (280 ) - Marketable securities (12 ) - Total deferred tax liabilities (357 ) (114 ) Total net deferred tax assets $ - $ - Reconciliation of Income Taxes: The main reconciling item between the statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowance in respect of deferred taxes relating to accumulated net operating losses carried forward due to the uncertainty of the realization of such deferred taxes. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data)

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 5 – SUBSEQUENT EVENTS At-the-market offerings subsequent to balance sheet date During October 2024, the Company issued 280,908 285	NOTE 16 – SUBSEQUENT EVENTS A. Preferred investment options inducement: On December 29, 2023, the Company entered into a preferred investment option exercise inducement offer letter with certain holders of existing (i) Series A preferred investment options to purchase 1,022,495 2.20 350,878 2.075 3.19 1,685,682 1.62 1,685,682 1.50 2,730 As mentioned in Note 9E above, the Company engaged Wainwright to act as its exclusive placement agent in connection with the transactions summarized above pursuant to an Engagement Letter, dated October 24, 2023 and paid Wainwright a cash fee equal to 7.0% 1.0% 60 16 84,284 2.025 , 2024 The Closing of the preferred investment option exercise inducement offer letter, and the modification of the previous warrants, the issuance of the stock and the warrants, and the receipt of cash, all occurred after December 31, 2023. B. Reinstatement of annual compensation: On January 8, 2024, the Board of Directors of the Company authorized the reinstatement of the annual fees payable to the independent directors for their services, effective as of January 1, 2024. Such fees were suspended in May 2023 as a result of the Company’s cost reduction plan. The Company also reinstated in full of the annual compensation of the CEO, effective as of January 1, 2024. Such compensation was reduced by 50 C. Settlement of litigation resulting from the 2017 financing: On January 26, 2024 (the “Effective Date”), the Company entered into a settlement agreement and release with the Plaintiffs (the “Settlement Agreement”), effectively resolving a lawsuit brought against the Company in 2020. The lawsuit stemmed from securities purchase agreements made between the Company and the third parties in 2017. Pursuant to the Settlement Agreement, the Company agreed to pay $ 2,154 1,100 1,005,965 MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) The Company concluded the Settlement Agreement gave rise to loss contingencies in the scope of ASC Subtopic 450-20, Contingencies – Loss Contingencies, and as of December 31, 2023, the Company recorded a contingent liability, as the Company deemed it both probable and reasonably estimable. The Company determined that the loss contingency should be recognized as non-operating losses, offset by loss recoveries received from the Company’s insurance company . As a result of the Settlement Agreement and the insurance recovery received from the insurance company, as of December 31, 2023, the Company recorded a liability and an asset on its balance sheet totaling $ 2,211 1,335 1,100 235 1,111 D. Stock option grants and other compensation: In February 2024, the Company granted the CEO, certain executives and certain employees, fully vested options to purchase an aggregate of 130,000 1.2684 132,500 1.25 In February 2024, the Company granted certain employees and advisors, options to purchase an aggregate of 77,500 1.2684 Regarding the CEO’s 2023 annual bonus, in February 2024, the Company paid the CEO 25% of his 2023 annual bonus, amounting to approximately $ 99 79,567 1.25 140 E. Return of CardioSert intellectual property assets: On March 3, 2024, the Company received notice from CardioSert that it was triggering its right to reacquire the Technology, pursuant to its rights under the CardioSert Agreement. The Company expects the transfer of the Technology back to CardioSert will occur in the second fiscal quarter of 2024.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of presentation		A. Basis of presentation The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”).
Financial statement in U.S. dollars		B. Financial statement in U.S. dollars The functional currency of the Company is the U.S. dollar (“dollar”) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future. Transactions and balances denominated in dollars are presented at their original amounts. Transactions and balances denominated in foreign currencies have been re-measured to dollars in accordance with the provisions of Accounting Standards Codification (“ASC”) 830-10, “Foreign Currency Translation”. All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statements of comprehensive loss as financial income or expenses, as appropriate.
Use of estimates	Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions pertaining to transactions and matters whose ultimate effect on the financial statements cannot precisely be determined at the time of financial statements preparation. Although these estimates are based on management’s best judgment, actual results may differ from these estimates.	C. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions pertaining to transactions and matters whose ultimate effect on the financial statements cannot precisely be determined at the time of financial statements preparation. Although these estimates are based on management’s best judgment, actual results may differ from these estimates. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Principles of consolidation		D. Principles of consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. Inter-company balances and transactions have been eliminated in consolidation.
Reclassification of prior year disclosures:		E. Reclassification of prior year disclosures: Certain prior year amounts have been reclassified for consistency with the current year disclosures. These reclassifications had no effect on the reported consolidated balance sheets, the related consolidated statements of comprehensive loss, shareholders’ equity and cash flows.
Acquisitions of assets		F. Acquisitions of assets The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is accounted for as business combination or an acquisition of assets.
Cash and cash equivalents		G. Cash and cash equivalents Cash and cash equivalents consist of cash and demand deposits in banks, and other short-term liquid investments (primarily interest-bearing time deposits) with original maturities of three months or less at the date of purchase.
Restricted cash		H. Restricted cash Restricted cash of $ 49 77
Fair value of financial instruments	Fair value of financial instruments The carrying values of cash and cash equivalents, other receivables and other accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of these instruments. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories: Level 1 Level 2 Level 3 The following tables summarizes the Company’s financial assets subject to fair value measurement and the level of inputs used in such measurements as of September 30, 2024 and December 31, 2023: SCHEDULE OF FINANCIAL ASSETS FAIR VALUE MEASUREMENT As of September 30, 2024 Total Level 1 Level 2 Level 3 Money market mutual funds $ 3,859 $ 3,859 $ - $ - As of December 31, 2023 Total Level 1 Level 2 Level 3 Marketable securities: U.S. treasury securities $ 2,497 $ 2,497 $ - $ - Money market mutual funds 1,420 1,420 - - $ 3,917 $ 3,917 $ - $ - The Company’s financial assets are measured at fair value on a recurring basis by level within the fair value hierarchy. The Company’s securities and money market funds are classified as Level 1. Other than that, the Company doesn’t have any other financial assets or financial liabilities marked to market at fair value as of September 30, 2024 and December 31, 2023.	I. Fair value of financial instruments The carrying values of cash and cash equivalents, other receivable and other accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of these instruments. The Company measures the fair value of certain of its financial instruments (such as marketable securities) on a recurring basis. The method of determining the fair value of marketable securities is discussed in Note 4 below. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories: Level 1 Level 2 Level 3
Concentrations of credit risk:		J. Concentrations of credit risk: Financial instruments which potentially subject the Company to credit risk consist primarily of cash and cash equivalents and marketable securities. The Company holds these investments in highly rated financial institutions. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Property and equipment		K. Property and equipment Property and equipment are presented at cost less accumulated depreciation. Depreciation is calculated based on the straight-line method over the estimated useful lives of the assets, at the following annual rates: SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT % Research equipment and software 25 33 Furniture and office equipment 7 Leasehold improvements Over the lease period The Company assesses property and equipment impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the property and equipment assets, or the appropriate grouping of assets, is compared to the carrying value to determine whether impairment exists. If an asset is determined to be impaired, the loss is measured based on the difference between the asset’s estimated fair value and its carrying value. For property and equipment assets, the estimate of fair value is typically based on a discounted cash flow model. As of December 31, 2023, and 2022, no impairment charge has been recorded.
Liabilities due to termination of employment agreements		L. Liabilities due to termination of employment agreements Under Israeli employment laws, employees of Microbot Israel are included under Article 14 of the Severance Compensation Act, 1963 (“Article 14”). According to Article 14, these employees are entitled to monthly deposits made by Microbot Israel on their behalf with insurance companies. Payments in accordance with Article 14 release Microbot Israel from any future severance payments (under the Israeli Severance Compensation Act, 1963) with respect of those employees. The aforementioned deposits are not recorded as an asset in the Company’s balance sheets. As for the U.S. employees, the Company has certain defined contribution plans, including a 401(k)-retirement plan in the U.S., whereby contributions made by eligible employees are matched by the Company with certain limitations.
Common stock warrants		M. Common stock warrants The Company accounts for warrants issued to investors as either equity-classified or liability-classified instruments, based on an assessment of the warrant’s specific terms and the applicable authoritative guidance in FASB ASC 480 and FASB ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, or meet all of the requirements for equity classification under FASB ASC 815, including whether the warrants are indexed to the Company’s own shares of common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.
Basic and diluted net loss per share		N. Basic and diluted net loss per share Basic net loss per share is calculated by dividing net loss attributable to common stock shareholders by the weighted average number of shares of common stock outstanding during the year without consideration of potentially dilutive securities. For purposes of the diluted net loss per share attributable to common shareholders calculation, stock options and warrants are considered to be common stock equivalents. All common stock equivalents have been excluded from the calculation of the diluted loss per share for the years ended December 31, 2023 and December 31, 2022, as their effect would be anti-dilutive. Therefore, basic and diluted net loss per share were the same for both years presented. In the calculation of the basic and diluted net loss, the Company included warrants that would be exercised for no or little consideration and are exercisable with no contingencies.
General and administrative expenses, net:		O. General and administrative expenses, net: General and administrative expenses are charged to the statement of comprehensive loss as incurred. Insurance loss recoveries are recognized when the amount is determinable and approved by the insurance company and applied as a deduction from general and administrative expenses. General and administrative expenses, net, for the years ended December 31, 2023 and 2022, were offset by insurance loss recoveries in the amounts of approximately $ 281 156
Research and development expenses, net:		P. Research and development expenses, net: Research and development expenses are charged to the statement of comprehensive loss as incurred. Grants for funding of approved research and development projects and others are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred and applied as a deduction from the research and development expenses. See Note 2V below. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Share-based compensation	Share-based compensation The Company applies ASC 718-10, “Share-Based Payment” (“ASC 718-10”), which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors including stock options under the Company’s stock plans based on estimated fair values. ASC 718-10 requires companies to estimate the fair value of stock options using an option-pricing model, which is recognized as an expense over the requisite service periods in the Company’s statement of comprehensive loss, based on a straight-line method. The Company recognizes compensation cost for an equity classified award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant date fair value of such award that is vested at that date. The Company recognizes the expense for an equity classified awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. If no explicit service period is determined, the Company estimates the implicit service period based on the timing the employee is expected to achieve the related performance condition. When no future services are required to be performed by the grantee in exchange for an award of equity instruments, and if such award does not contain a performance or market condition, the cost of the award is expensed on the grant date. The Company estimates the fair value of stock options granted as share-based payment awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on the standard deviation of the Company’s closing prices according to the expected life (SAB107) for each of the grants. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected stock option term is calculated for stock options granted using the “simplified” method for awards that qualify as “plain-vanilla” options. Changes in the determination of each of the inputs can affect the fair value of the stock options granted and the results of operations of the Company.	Q. Share-based compensation The Company applies ASC 718-10, “Share-Based Payment” (“ASC 718-10”), which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors including stock options under the Company’s stock plans based on estimated fair values. ASC 718-10 requires companies to estimate the fair value of stock options using an option-pricing model, which is recognized as an expense over the requisite service periods in the Company’s statement of comprehensive loss, based on a straight-line method. The Company recognizes compensation cost for an equity classified award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant date fair value of such award that is vested at that date. The Company estimates the fair value of stock options granted as share-based payment awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on the standard deviation of the Company’s closing prices according to the expected life (SAB107) for each of the grants. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected stock option term is calculated for stock options granted using the “simplified” method. Changes in the determination of each of the inputs can affect the fair value of the stock options granted and the results of operations of the Company.
Income taxes		R. Income taxes The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2023, and 2022, the Company had a full valuation allowance against deferred tax assets. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Marketable securities		S. Marketable securities The Company invests in various debt securities and an equity security. Debt securities consist of U.S. treasury securities. Equity security consist of a mutual fund. The Company records these investments in the consolidated balance sheet at fair value. For all of the Company’s debt securities, the Company elected the fair value option and thus all unrealized gains or losses for these securities are reflected in the statements of comprehensive loss as financial income or expenses, as appropriate. Unrealized gains or losses for the equity security are reflected in the statements of comprehensive loss as financial income or expenses, as appropriate. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.
Leases:		T. Leases: The Company determines if an arrangement is a lease at inception. Operating lease assets are presented as operating lease long-term right-of-use assets (“ROU”), and corresponding as lease liabilities (current portion), and as operating long-term lease liabilities, on the Company’s consolidated balance sheets. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the remaining lease payments over the lease term at commencement date. The Company’s leases do not provide an implicit interest rate. The Company calculates the incremental borrowing rate to reflect the interest rate that it would have to pay to borrow on a collateralized basis an amount equal to the lease payments in a similar economic environment over a similar term and considers the Company’s historical borrowing activities and market data in this determination. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that it will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which it accounts for as a single lease component. The Company has elected not to recognize ROU assets and lease liabilities for short-term leases that have a term of 12 months or less. The effect of short-term leases on the Company’s ROU assets and lease liabilities was not material. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. In addition, the Company does not have any related party leases. MICROBOT MEDICAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. dollars in thousands (Except share and per share data) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Contingencies	Contingencies Management records and discloses legal contingencies in accordance with ASC Topic 450 Contingencies. A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company monitors the stage of progress of its litigation matters to determine if any adjustments are required. The Company carries liability insurance to mitigate its exposure to losses, including litigation losses. The Company records the estimated amount of expected insurance proceeds for litigation losses incurred as an asset (typically a receivable from the insurer) and offset to losses up to the amount of the losses incurred when the amount is determinable and approved by the insurance company.	U. Contingencies: Management records and discloses legal contingencies in accordance with ASC Topic 450 Contingencies. A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company monitors the stage of progress of its litigation matters to determine if any adjustments are required. Refer to Note 16C below. The Company carries liability insurance to mitigate its exposure to losses, including litigation losses. The Company records the estimated amount of expected insurance proceeds for litigation losses incurred as an asset (typically a receivable from the insurer) and offset to losses up to the amount of the losses incurred when the amount is determinable and approved by the insurance company. Refer to Note 2O above and Note 16C below.
Government grants:		V Government grants: Government grants which are received from the Israeli Ministry of Economy and Israel Innovation Authority (“IIA”) by way of participation in research and development that is conducted by Microbot Israel, are received in installments as the program progresses based on qualified research spending. Grants received are recognized when the grant becomes receivable, provided there was reasonable assurance that Microbot Israel will comply with the conditions attached to the grant and there was reasonable assurance the grant will be received. The grants are deducted from the research and development expenses as the applicable costs are incurred. Research and development expenses, net, for the years ended December 31, 2023 and 2022, include participation in research and development expenses in the amount of approximately $ 279 0
Recently issued accounting pronouncements	Recently issued accounting pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption. Segment Reporting In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, to update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendment is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements and related disclosures.	W. Recently issued accounting pronouncements: From time to time, new accounting pronouncements are issued by FASB, or other standard-setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT		Property and equipment are presented at cost less accumulated depreciation. Depreciation is calculated based on the straight-line method over the estimated useful lives of the assets, at the following annual rates: SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT % Research equipment and software 25 33 Furniture and office equipment 7 Leasehold improvements Over the lease period
SCHEDULE OF FINANCIAL ASSETS FAIR VALUE MEASUREMENT	The following tables summarizes the Company’s financial assets subject to fair value measurement and the level of inputs used in such measurements as of September 30, 2024 and December 31, 2023: SCHEDULE OF FINANCIAL ASSETS FAIR VALUE MEASUREMENT As of September 30, 2024 Total Level 1 Level 2 Level 3 Money market mutual funds $ 3,859 $ 3,859 $ - $ - As of December 31, 2023 Total Level 1 Level 2 Level 3 Marketable securities: U.S. treasury securities $ 2,497 $ 2,497 $ - $ - Money market mutual funds 1,420 1,420 - - $ 3,917 $ 3,917 $ - $ -

CASH AND CASH EQUIVALENTS AND_2

CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES (Tables)	12 Months Ended
	Dec. 31, 2023
Cash and Cash Equivalents [Abstract]
SCHEDULE OF CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES	The following table sets forth our cash, cash equivalents and marketable securities as of December 31, 2023 and 2022: SCHEDULE OF CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES As of December 31, 2023 2022 Cash and cash equivalents: Cash $ 2,468 $ 1,195 U.S. treasury securities - 1,247 Total cash and cash equivalents $ 2,468 $ 2,442 Marketable securities: Money market mutual funds $ 1,420 $ 1,999 U.S. treasury securities 2,497 3,761 Total marketable securities $ 3,917 $ 5,760 Total cash, cash equivalents and marketable securities $ 6,385 $ 8,202

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Dec. 31, 2023
Fair Value Disclosures [Abstract]
SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES	The following table summarizes the Company’s financial assets subject to fair value measurement and the level of inputs used in such measurements as of December 31, 2023 and 2022: SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES As of December 31, 2023 Total Level 1 Level 2 Level 3 Marketable securities: U.S. treasury securities $ 2,497 $ 2,497 $ - $ - Money market mutual funds 1,420 1,420 - - $ 3,917 $ 3,917 $ - $ - As of December 31, 2022 Total Level 1 Level 2 Level 3 Cash equivalents: U.S. treasury securities $ 1,247 $ 1,247 $ - $ - Marketable securities: U.S. treasury securities $ 3,761 $ 3,761 $ - $ - Money market mutual funds 1,999 1,999 - - $ 5,760 $ 5,760 $ - $ -

PREPAID EXPENSES AND OTHER CU_2

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)	12 Months Ended
	Dec. 31, 2023
Prepaid Expenses And Other Current Assets
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS	SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS As of December 31, 2023 2022 Amounts due from government institutions $ 61 $ 103 Prepaid expenses and other receivables 91 429 Total prepaid expenses and other current assets $ 152 $ 532

LEASES (Tables)

LEASES (Tables)	12 Months Ended
	Dec. 31, 2023
Leases [Abstract]
SCHEDULE OF STATEMENTS OF COMPREHENSIVE LOSS	The following table presents the components of the Company’s lease cost and the classification of such costs in the Company’s consolidated statements of comprehensive loss for the years ended December 31, 2023 and 2022: SCHEDULE OF STATEMENTS OF COMPREHENSIVE LOSS Component of Lease Cost Statements of Comprehensive Loss Line Item 2023 2022 For the Years Ended December 31, Component of Lease Cost Statements of Comprehensive Loss Line Item 2023 2022 Operating lease cost Research and development, net $ 279 $ 300
SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES	Supplemental cash flow information related to operating leases was as follows: SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES 2023 2022 For the Years Ended December 31, 2023 2022 Cash paid under operating lease agreements $ 283 $ 344
SCHEDULE OF MATURITIES OF LEASE LIABILITIES	Undiscounted maturities of future operating lease payments as of December 31, 2023 are summarized as follows: SCHEDULE OF MATURITIES OF LEASE LIABILITIES As of December 31, 2023 2024 $ 208 2025 48 2026 21 Total future lease payments 277 Less imputed interest (47 ) Total lease liabilities $ 231
SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES	The following table includes the weighted-average lease terms and discount rates for operating leases as of December 31, 2023 and 2022: SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES As of December 31, 2023 2022 Operating leases weighted average remaining lease term (in years) 0.8 2 Operating leases weighted average discount rate 7 % 9 %

PROPERTY AND EQUIPMENT, NET (Ta

PROPERTY AND EQUIPMENT, NET (Tables)	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT	SCHEDULE OF PROPERTY AND EQUIPMENT 2023 2022 As of December 31, 2023 2022 Historical Cost: Research equipment and software $ 177 $ 143 Leasehold improvement 229 229 Furniture and office equipment 233 236 Cost 639 608 Accumulated Depreciation: Research equipment and software 109 63 Leasehold improvement 181 135 Furniture and office equipment 203 189 Accumulated Depreciation 493 387 Net book value $ 146 $ 221

ACCRUED LIABILITIES (Tables)

ACCRUED LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2023
Payables and Accruals [Abstract]
SCHEDULE OF ACCRUED LIABILITIES	SCHEDULE OF ACCRUED LIABILITIES As of December 31, 2023 2022 Employee-related liabilities $ 725 $ 1,372 Other current liabilities 302 298 Total Accrued Liabilities $ 1,027 $ 1,670

SHARE CAPITAL (Tables)

SHARE CAPITAL (Tables)	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
SCHEDULE OF GRANT DATE FAIR VALUE OF PREFERRED INVESTMENT OPTIONS ISSUED TO INVESTORS	The grant date fair values of preferred investment options issued to Wainwright and preferred investment options issued to investors that were modified in the years ended December 31, 2023 and 2022 were estimated using the Black-Scholes valuation model with the following: SCHEDULE OF GRANT DATE FAIR VALUE OF PREFERRED INVESTMENT OPTIONS ISSUED TO INVESTORS For the Years Ended December 31, 2023 2022 Expected volatility 101.31 122.39 87.96 % Risk-free interest 3.85 4.93 4.25 % Dividend yield - - Expected terms (years) 1.42 5 4.99
SUMMARY OF STOCK OPTION ACTIVITY	SUMMARY OF STOCK OPTION ACTIVITY For the Year Ended December 31, 2023 Number of stock options Weighted average exercise price Outstanding as of December 31, 2022 1,507,137 $ 7.31 Granted 711,308 1.75 Forfeitures (123,083 ) 5.78 Outstanding as of December 31, 2023 2,095,362 $ 5.51 Vested as of December 31, 2023 1,176,118 $ 7.74 For the Year Ended December 31, 2022 Number of stock options Weighted average exercise price Outstanding as of December 31, 2021 997,148 $ 8.48 Granted 530,822 5.14 Forfeitures (20,833 ) 8.16 Outstanding as of December 31, 2022 1,507,137 $ 7.31 Vested as of December 31, 2022 899,609 $ 8.52
SCHEDULE OF STOCK OPTIONS OUTSTANDING	The stock options outstanding as of December 31, 2023 and December 31, 2022, summarized by exercise prices, are as follows: SCHEDULE OF STOCK OPTIONS OUTSTANDING Exercise price $ Stock options outstanding as of December 31, 2023 Stock options outstanding as of December 31, 2022 Weighted average remaining contractual life – years as of December 31, 2023 Weighted average remaining contractual life – years as of December 31, 2022 Stock options exercisable as of December 31, 2023 Stock options exercisable as of December 31, 2022 0.00 0.01 61,577 61,577 2.3 3.3 61,577 61,577 1.00 3.73 860,808 211,000 9.6 10 95,925 - 4.2 7.26 639,232 687,482 6.3 8.0 484,871 315,807 8.16 9.64 380,872 380,872 6.6 7.6 380,872 356,019 15.3 15.75 152,873 166,206 3.7 4.8 152,873 166,206 2,095,362 1,507,137 1,176,118 899,609
SCHEDULE OF STOCK OPTIONS VALUATION ASSUMPTIONS	The grant date fair values of employee stock options granted in the years ended December 31, 2023 and 2022 were estimated using the Black-Scholes valuation model with the following: SCHEDULE OF STOCK OPTIONS VALUATION ASSUMPTIONS For the Years Ended December 31, 2023 2022 Expected volatility 86.5% 98.2 111.2% 161.7% Risk-free interest 3.3 4.7% 1.7% 3.7% Dividend yield - - Expected terms (years) 5.8 6.2
SCHEDULE OF WARRANTS OUTSTANDING	The remaining outstanding warrants and terms as of December 31, 2023 and 2022 are as follows: SCHEDULE OF WARRANTS OUTSTANDING Issuance date Outstanding and exercisable as of December 31, 2023 Outstanding and exercisable as of December 31, 2022 Exercise Price Exercisable Through Series A (2013) - 183 $ 2,754.00 April 9, 2023 Warrant to underwriters December 2019 - 45,643 $ 13.13 June 25, 2023 Warrant to underwriters December 2019 - 47,619 $ 13.13 June 27, 2023 Warrant to underwriters December 2019 - 45,045 $ 13.88 June 30, 2023 Series A October 2022 1,022,495 1,022,495 $ 2.20 October 25, 2027 Series B October 2022 - 1,022,495 $ 2.20 October 25, 2027 Prefunded warrants October 2022 - 240,000 $ (* ) No limit Warrant to underwriters October 2022 51,125 51,125 $ 6.11 October 21, 2027 Warrant to underwriters May 2023 32,778 - $ 2.75 November 23, 2026 Warrant to underwriters May 2023 60,476 - $ 2.75 November 24, 2026 Warrant to underwriters June 2023 35,088 - $ 2.67 June 2, 2028 Warrant series C June 2023 350,878 - $ 2.08 December 6, 2028 Warrant to underwriters June 2023 31,231 - $ 4.06 June 28, 2028 Warrant series D June 2023 312,309 - $ 3.19 December 28, 2028 (*) Less than $0.01.

BASIC AND DILUTED NET LOSS PE_2

BASIC AND DILUTED NET LOSS PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES EXCLUDED FROM DILUTED LOSS PER SHARE	SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES EXCLUDED FROM DILUTED LOSS PER SHARE 2023 2022 For the Years Ended December 31, 2023 2022 Series A 2013 - 183 Warrant to underwriters December 2019 - 45,643 Warrant to underwriters December 2019 - 47,619 Warrant to underwriters December 2019 - 45,045 Series A and B warrants October 2022 1,022,495 2,044,990 Warrant to underwriters October 2022 51,125 51,125 Warrant to underwriters May 2023 32,778 - Warrant to underwriters May 2023 60,476 - Warrant to underwriters June 2023 35,088 - Warrant series C June 2023 350,878 - Warrant to underwriters June 2023 31,231 - Warrant series D June 2023 312,309 - Outstanding employee stock options to purchase common stock 2,095,362 1,507,137 Potentially dilutive securities excluded from diluted loss per share 2,095,362 1,507,137

RESEARCH AND DEVELOPMENT EXPE_2

RESEARCH AND DEVELOPMENT EXPENSES, NET (Tables)	12 Months Ended
	Dec. 31, 2023
Research and Development [Abstract]
SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES	SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES 2023 2022 For the Years Ended December 31, 2023 2022 Payroll and related expenses $ 2,455 $ 3,558 Share-based compensation 407 387 Professional services 1,842 2,097 Materials 520 559 Patents 157 341 Rent 213 224 Office and maintenance expenses 55 100 Depreciation 106 102 Other 248 368 Less - grants (279 ) - Research and development expense $ 5,724 $ 7,736

GENERAL AND ADMINISTRATIVE EX_2

GENERAL AND ADMINISTRATIVE EXPENSES, NET (Tables)	12 Months Ended
	Dec. 31, 2023
General And Administrative Expenses Net
SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES	SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES 2023 2022 For the Years Ended December 31, 2023 2022 Payroll and related expenses $ 1,223 $ 1,813 Government fees 58 35 Share-based compensation 988 1,365 Professional services 1,204 1,154 Insurance 442 733 Public and investor relations 148 220 Office and maintenance expenses 95 120 Travel 160 180 Other 94 81 Less – insurance loss recoveries (281 ) (156 ) General and administrative expenses $ 4,131 $ 5,545

TAXES ON INCOME (Tables)

TAXES ON INCOME (Tables)	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES	SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES 2023 2022 As of December 31, 2023 2022 Net operating loss carryforwards $ 115,778 $ 113,393 Operating lease liabilities 53 105 Accrued vacation pay 59 71 Legal settlement accrual 464 - Advance payment from IIA 17 - Total deferred tax assets 116,371 113,569 Less: valuation allowance (116,014 ) (113,455 ) Net deferred tax assets 357 114 Operating leases, right-of-use assets (60 ) (114 ) Grant receivable ( Ministry of Economy) (5 ) - Insurance recovery receivable (280 ) - Marketable securities (12 ) - Total deferred tax liabilities (357 ) (114 ) Total net deferred tax assets $ - $ -

GENERAL (Details Narrative)

GENERAL (Details Narrative) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Date of incorporation	Aug. 02, 1988	Aug. 02, 1988
Cash equivalents and marketable securities	$ 4,338	$ 6,385	$ 8,202

SCHEDULE OF ESTIMATED USEFUL LI

SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)	Dec. 31, 2023
Research Equipment and Software [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	25 years
Research Equipment and Software [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	33 years
Furniture and Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	7 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]	Useful Life, Lease Term [Member]

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
General and Administrative Expense [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Insurance	$ 281,000	$ 156,000
Research and Development Expense [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Government grants	279,000	0
Collateral Lease Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Restricted cash	$ 49	$ 77

SCHEDULE OF CASH AND CASH EQUIV

SCHEDULE OF CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash and Cash Equivalents [Line Items]
Total cash and cash equivalents		$ 2,468	$ 2,442
Total marketable securities	$ 3,859	3,917	5,760
Total cash, cash equivalents and marketable securities	$ 4,338	6,385	8,202
Money Market Funds [Member]
Cash and Cash Equivalents [Line Items]
Total marketable securities		1,420	1,999
US Treasury Securities [Member]
Cash and Cash Equivalents [Line Items]
Total marketable securities		2,497	3,761
Cash [Member]
Cash and Cash Equivalents [Line Items]
Total cash and cash equivalents		2,468	1,195
US Treasury Securities [Member]
Cash and Cash Equivalents [Line Items]
Total cash and cash equivalents			$ 1,247

CASH AND CASH EQUIVALENTS AND_3

CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash and Cash Equivalents [Abstract]
Unrealized gains on marketable securities	$ 59	$ 12

SCHEDULE OF FAIR VALUE MEASUREM

SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Marketable Securities [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Assets, fair value	$ 3,859	$ 3,917	$ 5,760
Marketable Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Assets, fair value	3,859	3,917	5,760
Marketable Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Assets, fair value
Marketable Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Assets, fair value
US Treasury Securities [Member] | Marketable Securities [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Assets, fair value		2,497	3,761
US Treasury Securities [Member] | Marketable Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Assets, fair value		2,497	3,761
US Treasury Securities [Member] | Marketable Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Assets, fair value
US Treasury Securities [Member] | Marketable Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Assets, fair value
US Treasury Securities [Member] | Cash Equivalents [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Assets, fair value			1,247
US Treasury Securities [Member] | Cash Equivalents [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Assets, fair value			1,247
US Treasury Securities [Member] | Cash Equivalents [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Assets, fair value
US Treasury Securities [Member] | Cash Equivalents [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Assets, fair value
Money Market Funds [Member] | Marketable Securities [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Assets, fair value		1,420	1,999
Money Market Funds [Member] | Marketable Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Assets, fair value		1,420	1,999
Money Market Funds [Member] | Marketable Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Assets, fair value
Money Market Funds [Member] | Marketable Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Assets, fair value

SCHEDULE OF PREPAID EXPENSES AN

SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Prepaid Expenses And Other Current Assets
Amounts due from government institutions		$ 61	$ 103
Prepaid expenses and other receivables		91	429
Total prepaid expenses and other current assets	$ 609	$ 152	$ 532

SCHEDULE OF STATEMENTS OF COMPR

SCHEDULE OF STATEMENTS OF COMPREHENSIVE LOSS (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Research And Development Net [Member]
Operating lease cost	$ 279	$ 300

SCHEDULE OF SUPPLEMENTAL CASH F

SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Cash paid under operating lease agreements	$ 283	$ 344

SCHEDULE OF MATURITIES OF LEASE

SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Leases [Abstract]
2024	$ 208
2025	48
2026	21
Total future lease payments	277
Less imputed interest	(47)
Total lease liabilities	$ 231

SCHEDULE OF SUPPLEMENTAL INFORM

SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES (Details)	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Operating leases weighted average remaining lease term (in years)	9 months 18 days	2 years
Operating leases weighted average discount rate	7%	9%

LEASES (Details Narrative)

LEASES (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Nov. 30, 2019
Leases [Abstract]
Lessee, Operating Lease, Term of Contract		5 years
Finance Lease, Principal Payments	$ 16
Bank guarantee issued	$ 49

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Cost		$ 639	$ 608
Accumulated Depreciation		493	387
Net book value	$ 99	146	221
Research Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Cost		177	143
Accumulated Depreciation		109	63
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Cost		229	229
Accumulated Depreciation		181	135
Furniture and Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Cost		233	236
Accumulated Depreciation		$ 203	$ 189

SCHEDULE OF ACCRUED LIABILITIES

SCHEDULE OF ACCRUED LIABILITIES (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Employee-related liabilities		$ 725	$ 1,372
Other current liabilities		302	298
Total Accrued Liabilities	$ 1,060	$ 1,027	$ 1,670

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative)																1 Months Ended					3 Months Ended							9 Months Ended		12 Months Ended
	Jul. 17, 2024 USD ($)	Jul. 01, 2024 USD ($)	Jun. 30, 2024 USD ($)	Jun. 03, 2024 shares	Feb. 29, 2024 USD ($)	Jan. 26, 2024 USD ($) shares	Aug. 22, 2023 USD ($)	Jun. 26, 2023 shares	Jun. 02, 2023 shares	May 23, 2023 shares	Oct. 06, 2022 USD ($)	Oct. 03, 2022 USD ($)	Mar. 31, 2021 USD ($)	Apr. 28, 2019 USD ($)	Jan. 04, 2018 USD ($) $ / shares shares	Dec. 31, 2024 USD ($)	Sep. 30, 2024 USD ($)	Jul. 31, 2024 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2012	Sep. 30, 2024 USD ($) shares	Jun. 30, 2024 USD ($) shares		Mar. 31, 2024 USD ($) shares		Jun. 30, 2023 USD ($) shares		Sep. 30, 2024 USD ($) shares	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($) shares		Dec. 31, 2022 USD ($) shares		Sep. 30, 2024 ILS (₪)	Dec. 31, 2023 ILS (₪)	Dec. 11, 2022 USD ($)	Dec. 11, 2022 ILS (₪)	Jun. 10, 2021 USD ($)
Net sales royalty percenatge																												3%		3%
Gross proceeds from cash fee percentage												7%
Gross proceeds from management fee percentage												1%
Stock issued during period, value, new issues																						$ 2,022,000	[1]	$ 2,397,000	[2]	$ 6,558,000				$ 6,558,000	[3]	$ 4,324,000	[4]
Litigation settlement amount						$ 2,154,000
Settlement agreement liability																														2,211,000
Insurance recoverable																														1,335,000
Settlement amount recovery																														1,100,000
Legal expense																														235,000
Non operating loss on legal settlement																														1,111,000
New funds not raise																												$ 5,104,000	$ 6,558,000	6,558,000		4,324,000
Common Stock [Member]
Stock issued during period, value, new issues																						$ 16,000	[1]	$ 17,000	[2]	$ 35,000				$ 38,000	[3]	$ 8,000	[4]
Number of share issued | shares																						1,566,669	[1]	1,685,682	[2]	3,576,689	[2]			3,816,689	[3]	782,495	[4]
Joseph Mona [Member]
Purchase price of plaintiffs							$ 485,000						$ 485,000
Chief Executive Officer [Member]
Contingent cash bonus	$ 149,000		$ 149,000														$ 149,000		$ 149,000		$ 149,000	$ 149,000						149,000
Percentage of contingent cash bonus	50%																50%		50%
Chief Executive Officer [Member] | Forecast [Member]
New funds not raise																$ 10,000,000
Other Executives [Member]
Contingent cash bonus																	$ 61,000				61,000							61,000						₪ 230,736
New funds not raise	$ 3,000,000				$ 3,000,000
Chief Financial Officer And Chief Technology Officer [Member]
Contingent cash bonus																	61,000				$ 61,000							61,000
Device [Member]
Royalties percentage											3%
Integrated Product [Member]
Royalties percentage											1.50%
At-the-Market Offering Agreement [Member] | Common Stock [Member]
Sale of Stock, Consideration Received on Transaction		$ 4,820,000
Percentage of placement fee		3%
Number of share issued | shares																					685,800
Securities Purchase Agreement [Member]
Purchase price of plaintiffs																												$ 6,750,000		$ 6,750,000
Securities Purchase Agreement [Member] | Common Stock [Member]
Number of share issued | shares				1,566,669				624,618	701,756	975,000
Cardio Sert [Member]
Aggregate amount																		$ 530,000
Litigation Settlement [Member]
Payment for litigation settlement						$ 1,100,000																		$ 1,100,000
Restricted common shares issued for legal settlement | shares						1,005,965
Insurance recovery amount																								$ 1,335,000
Litigation Settlement [Member] | Common Stock [Member]
Number of share issued | shares																								1,005,965				1,005,965
Minimum [Member] | Chief Executive Officer [Member]
New funds not raise			$ 3,000,000														6,000,000		$ 3,000,000
Maximum [Member] | Chief Executive Officer [Member]
Contingent cash bonus					$ 298,000
Israeli Innovation Authority [Member]
Grants receivable																	378,000				$ 378,000							$ 378,000		304					₪ 27,000	$ 83,000	₪ 300,000
Additional grant receivable																	447,000				447,000							$ 447,000		$ 447				₪ 1,620,000	₪ 1,620,000
Israeli Innovation Authority [Member] | Minimum [Member]
Net sales royalty percenatge																												3%		3%
Israeli Innovation Authority [Member] | Maximum [Member]
Net sales royalty percenatge																												5%		5%
Israeli Innovation Authority [Member] | CardioSert Ltd [Member]
Repayment of government grants															$ 530,000
Israeli Innovation Authority [Member] | Nitiloop [Member]
Repayment of government grants											$ 925,000
Technion Research and Development Foundation Limited [Member] | Minimum [Member]
Net sales royalty percenatge																				1.50%
Technion Research and Development Foundation Limited [Member] | Maximum [Member]
Net sales royalty percenatge																				3%
CardioSert Ltd [Member] | Technology [Member]
Payment to acquire intangible assets															$ 300,000
Number of common shares issued for acquisition | shares															6,738
Number of common shares issued for acquisition, value															$ 74,000
Buy back amount per patent | $ / shares															$ 1
Consulting fee description															Additionally, the CardioSert Agreement may be terminated by either party upon breach of the other (subject to cure). Until May 2023, Microbot Israel paid CardioSert a monthly consultation fee of NIS
Professional Fees															$ 40,000,000
Monthly consultation fee in USD | $ / shares															$ 11
Currency exchange rate, description															exchange rate of NIS 3.7 to the dollar)
CardioSert Ltd [Member] | Minimum [Member] | Technology [Member]
Investments															$ 2,000,000
H.C. Wainwright & Co. LLC [Member]
Professional Fees												$ 565,000
Warrant issued, descriptions												The Company has also agreed to issue to Wainwright or its designees preferred investment options upon the closing of such offerings, equal to five (5.0%) percent of the aggregate number of such shares of common stock in such offerings, including upon exercise for cash of any warrants issued to investors in such offering.
H.C. Wainwright & Co. LLC [Member] | At-the-Market Offering Agreement [Member]
Offering costs																																						$ 10,000,000
Stock issued during period, value, new issues											$ 8,000,000
H.C. Wainwright & Co. LLC [Member] | Securities Purchase Agreement [Member] | Common Stock [Member]
Number of share issued | shares								31,231
Alliance Investment Management, Ltd. [Member]
Litigation settlement														$ 468,000
Ministry Of Economy [Member]
Grants receivable																	$ 50,000				$ 50,000							$ 50,000
2013 Through June 30, 2022 [Member] | Israeli Innovation Authority [Member]
Revenue grants received																														$ 1,804,000
Two Thousand Thirteen Through June Thirty Two Thousand Twenty Four [Member] | Israeli Innovation Authority [Member]
Revenue grants received																												$ 1,878,000
[1]Net of issuance costs in the amount of approximately $ 328 333 1,075 676

SCHEDULE OF GRANT DATE FAIR VAL

SCHEDULE OF GRANT DATE FAIR VALUE OF PREFERRED INVESTMENT OPTIONS ISSUED TO INVESTORS (Details)	Dec. 31, 2023	Dec. 31, 2022
Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input		87.96
Measurement Input, Price Volatility [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	101.31
Measurement Input, Price Volatility [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	122.39
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input		4.25
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	3.85
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	4.93
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input
Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected terms (years)		4 years 11 months 26 days
Measurement Input, Expected Term [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected terms (years)	1 year 5 months 1 day
Measurement Input, Expected Term [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected terms (years)	5 years

SUMMARY OF STOCK OPTION ACTIVIT

SUMMARY OF STOCK OPTION ACTIVITY (Details) - Employees and Directors [Member] - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Number of stock options outstanding, Outstanding at beginning of period	1,507,137	997,148
Weighted average exercise price, Outstanding at beginning of period	$ 7.31	$ 8.48
Number of stock options outstanding, Granted	711,308	530,822
Weighted average exercise price, Granted	$ 1.75	$ 5.14
Number of stock options outstanding, forfeitures	(123,083)	(20,833)
Weighted average exercise price, forfeitures	$ 5.78	$ 8.16
Number of stock options outstanding, Outstanding at end of period	2,095,362	1,507,137
Weighted average exercise price, Outstanding at end of period	$ 5.51	$ 7.31
Number of stock options outstanding, Vested at end of period	1,176,118	899,609
Weighted average exercise price, Vested at end of period	$ 7.74	$ 8.52

SCHEDULE OF STOCK OPTIONS OUTST

SCHEDULE OF STOCK OPTIONS OUTSTANDING (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Stock options outstanding	2,095,362	1,507,137
Stock options exercisable	1,176,118	899,609
Exercise Price One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Stock options outstanding	61,577	61,577
Weighted average remaining contractual life	2 years 3 months 18 days	3 years 3 months 18 days
Stock options exercisable	61,577	61,577
Exercise Price One [Member] | Minimum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 0	$ 0
Exercise Price One [Member] | Maximum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 0.01	$ 0.01
Exercise Price Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Stock options outstanding	860,808	211,000
Weighted average remaining contractual life	9 years 7 months 6 days	10 years
Stock options exercisable	95,925
Exercise Price Two [Member] | Minimum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 1	$ 1
Exercise Price Two [Member] | Maximum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 3.73	$ 3.73
Exercise Price Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Stock options outstanding	639,232	687,482
Weighted average remaining contractual life	6 years 3 months 18 days	8 years
Stock options exercisable	484,871	315,807
Exercise Price Three [Member] | Minimum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 4.2	$ 4.2
Exercise Price Three [Member] | Maximum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 7.26	$ 7.26
Exercise Price Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Stock options outstanding	380,872	380,872
Weighted average remaining contractual life	6 years 7 months 6 days	7 years 7 months 6 days
Stock options exercisable	380,872	356,019
Exercise Price Four [Member] | Minimum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 8.16	$ 8.16
Exercise Price Four [Member] | Maximum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 9.64	$ 9.64
Exercise Price Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Stock options outstanding	152,873	166,206
Weighted average remaining contractual life	3 years 8 months 12 days	4 years 9 months 18 days
Stock options exercisable	152,873	166,206
Exercise Price Five [Member] | Minimum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 15.3	$ 15.3
Exercise Price Five [Member] | Maximum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 15.75	$ 15.75

SCHEDULE OF STOCK OPTIONS VALUA

SCHEDULE OF STOCK OPTIONS VALUATION ASSUMPTIONS (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Equity [Abstract]
Expected volatility, minimum	86.50%	111.20%
Expected volatility, maximum	98.20%	161.70%
Risk-free interest, minimum	3.30%	1.70%
Risk-free interest, maximum	4.70%	3.70%
Dividend yield
Expected terms (years)	5 years 9 months 18 days	6 years 2 months 12 days

SCHEDULE OF WARRANTS OUTSTANDIN

SCHEDULE OF WARRANTS OUTSTANDING (Details) - $ / shares		12 Months Ended
		Dec. 31, 2023	Feb. 13, 2023	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of outstanding warrants			240,000
Exercise price			$ 0.0001
Series A (2013) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of outstanding warrants				183
Exercise price		$ 2,754
Exercisable Through		April 9, 2023
Warrant To Underwriters Two Thousand Nineteen December One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of outstanding warrants				45,643
Exercise price		$ 13.13
Exercisable Through		June 25, 2023
Warrant To Underwriters Two Thousand Nineteen December Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of outstanding warrants				47,619
Exercise price		$ 13.13
Exercisable Through		June 27, 2023
Warrant To Underwriters Two Thousand Nineteen December Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of outstanding warrants				45,045
Exercise price		$ 13.88
Exercisable Through		June 30, 2023
Series A Warrant October Two Thousand Twenty Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of outstanding warrants		1,022,495		1,022,495
Exercise price		$ 2.20
Exercisable Through		October 25, 2027
Series B Warrant October Two Thousand Twenty Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of outstanding warrants				1,022,495
Exercise price		$ 2.20
Exercisable Through		October 25, 2027
Pre Funded Warrants October Two Thousand Twenty Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of outstanding warrants				240,000
Exercise price	[1]
Exercisable Through		No limit
Warrant To Underwriters October Two Thousand Twenty Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of outstanding warrants		51,125		51,125
Exercise price		$ 6.11
Exercisable Through		October 21, 2027
Warrant To Underwriters One May Two Thousand Twenty Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of outstanding warrants		32,778
Exercise price		$ 2.75
Exercisable Through		November 23, 2026
Warrant To Underwriters Two May Two Thousand Twenty Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of outstanding warrants		60,476
Exercise price		$ 2.75
Exercisable Through		November 24, 2026
Warrant To Underwriters One June Two Thousand Twenty Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of outstanding warrants		35,088
Exercise price		$ 2.67
Exercisable Through		June 2, 2028
Warrant Series C June Two Thousand Twenty Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of outstanding warrants		350,878
Exercise price		$ 2.08
Exercisable Through		December 6, 2028
Warrant To Underwriters Two June Two Thousand Twenty Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of outstanding warrants		31,231
Exercise price		$ 4.06
Exercisable Through		June 28, 2028
Warrant Series D June Two Thousand Twenty Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of outstanding warrants		312,309
Exercise price		$ 3.19
Exercisable Through		December 28, 2028
[1]Less than $0.01.

SHARE CAPITAL (Details Narrativ

SHARE CAPITAL (Details Narrative) - USD ($)																	1 Months Ended		3 Months Ended							9 Months Ended	12 Months Ended
	Jul. 01, 2024	Jun. 03, 2024	Feb. 29, 2024	Dec. 29, 2023	Oct. 25, 2023	Jun. 28, 2023	Jun. 26, 2023	Jun. 16, 2023	Jun. 06, 2023	Jun. 02, 2023	May 23, 2023	May 22, 2023	Oct. 25, 2022	Oct. 21, 2022	Oct. 03, 2022	Oct. 03, 2022	Sep. 30, 2024	Feb. 29, 2024	Sep. 30, 2024	Jun. 30, 2024		Mar. 31, 2024		Jun. 30, 2023	[2]	Sep. 30, 2024	Dec. 31, 2023		Dec. 31, 2022		Jun. 29, 2023	Feb. 13, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares issued																	16,651,433		16,651,433							16,651,433	11,707,317		7,890,628
Common stock, shares outstanding																	16,651,433		16,651,433							16,651,433	11,707,317		7,890,628
Exercise price																																$ 0.0001
Warrants exercise price														$ 0.0001
Fair value of warrants							$ 68,000			$ 58,000	$ 72,000	$ 46,000				$ 138,000											$ 1,230
Warrants outstanding																																240,000
Aggregate intrinsic value of outstanding options																											277,000		$ 185,000
Aggregate intrinsic value of exercisable options																											$ 102,000		$ 185,000
Weighted average grant date fair value of options granted																											$ 1.40		$ 4.5
Unrecognized compensation costs, net of expected forfeitures																											$ 1,918,000
Unrecognized compensation weighted average period																											2 years 4 months 24 days
Existing investment options				$ 2,730,000
Agent fees and other offering expenses				$ 333,000
Common stock, par value																	$ 0.01		$ 0.01							$ 0.01	$ 0.01		$ 0.01
Net of issuance costs																			$ 49,000	$ 328,000		$ 333,000					$ 1,075,000		$ 676,000
Annual bonus			$ 99,000
Chief Executive Officer [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share price per share			$ 1.25															$ 1.25
Agggregate number of options granted																		79,567
Compensation percentage																		25%
Chief Executive Officer Executives And Employees [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share price per share			1.2684															$ 1.2684
Agggregate number of options granted																		130,000
Chief Executive Officer And Other Executives [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share price per share			1.25															$ 1.25
Agggregate number of options granted																		132,500
Chief Executive Officer Employees And Advisors [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share price per share			$ 1.2684															$ 1.2684
Agggregate number of options granted																		195,000
Stock option vested term																		3 years
Advisors [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share price per share																	$ 0.8558		$ 0.8558							$ 0.8558
Agggregate number of options granted																	25,000
Stock option vested term																	3 years
Series B Preferred Investment Options [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expiry date					Oct. 25, 2027
Options exercise price per share					$ 2.20
Preferred Investment Option Exercise Inducement Offers Letter [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issued shares				1,022,495					350,878
Share price per share							$ 3.19		$ 2.075																						$ 1.62
Options exercise price per share													$ 2.20
H.C. Wainwright & Co. LLC [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price															$ 6.11	$ 6.11
Prefunded warrants exercisable															51,125	51,125
Professional Fees															$ 565,000
Offering expenses															$ 111,000	$ 111,000
Warrants and Rights Outstanding, Term															5 years	5 years
H.C. Wainwright & Co. LLC [Member] | Preferred Investment Option Exercise Inducement Offers Letter [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issued shares				84,284
Share price per share				$ 2.025
Series A Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issued shares														1,022,495
Share price per share														$ 4.64
Series B Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issued shares														1,022,495
Share price per share														$ 4.64
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issued shares																				1,566,669	[1]	1,685,682	[2]	3,576,689			3,816,689	[3]	782,495	[4]
Common Stock [Member] | Mr. Harel Gadot [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Agggregate number of options granted																													260,000
Stock option vested term																													3 years
Common Stock [Member] | Mr. Harel Gadot [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted-average exercise price per share, granted																													$ 3.73
Common Stock [Member] | Mr. Harel Gadot [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted-average exercise price per share, granted																													$ 6.48
Common Stock [Member] | Employees Consultants and Directors [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Agggregate number of options granted																											631,308		270,822
Stock option vested term																											3 years		3 years
Common Stock [Member] | Employees Consultants and Directors [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted-average exercise price per share, granted																											$ 1.16		$ 3.73
Common Stock [Member] | Employees Consultants and Directors [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted-average exercise price per share, granted																											$ 3.48		$ 6.48
Common Stock [Member] | Chief Executive Officer [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Agggregate number of options granted																											80,000
Weighted-average exercise price per share, granted																											$ 2.43
Stock option vested term																													3 years
Common Stock [Member] | Series B Preferred Investment Options [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cashless exercise of shares								385,246
Common Stock [Member] | Private Placement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issued shares										35,088
Share price per share										$ 2.6719
Offering expenses		$ 328,000					$ 281,000			$ 227,000	345,000	222,000
Gross proceeds		$ 2,350,000					$ 2,030,000			$ 1,500,000	$ 2,661,000	$ 1,442,000
Common Stock [Member] | Series D Preferred Investment Options [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issued shares						312,309	312,309				60,476	32,778
Share price per share						$ 3.19	$ 3.19				$ 2.1999
Common Stock [Member] | Series C Preferred Investment Options [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issued shares									350,878	350,878
Share price per share									$ 2.075	$ 2.075
Common Stock [Member] | Series A Preferred Investment Options [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issued shares													1,022,495														1,022,495
Share price per share													$ 2.20														$ 4.64
Expiry date																											Oct. 25, 2027
Common Stock [Member] | Series B Preferred Investment Options [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issued shares																											1,022,495
Share price per share																											$ 4.64
Expiry date																											Oct. 25, 2024
Common Stock [Member] | Existing Preferred Investment Options [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issued shares				1,685,682
Share price per share				$ 1.62
Common Stock [Member] | Inducement Investment Options [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issued shares				1,685,682
Share price per share				$ 1.50
Common Stock [Member] | Series F Preferred Investment Options [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issued shares		3,133,338
Share price per share		$ 1.50
Purchase Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issued shares														782,495
Exercise price														$ 4.89
Purchase Agreement [Member] | Investor [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price														$ 4.8899
Prefunded warrants exercisable														240,000
Proceeds from warrants offerings														$ 5,000,000
Securities Purchase Agreement [Member] | Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issued shares		1,566,669					624,618			701,756	975,000
Prefunded warrants exercisable											234,500
Share price per share		$ 1.50					$ 3.25			$ 2.1375	$ 2.20	$ 2.75															$ 0.0001
Common stock, par value		$ 0.01
Securities Purchase Agreement [Member] | Common Stock [Member] | Private Placement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issued shares												655,569
Share price per share												$ 2.20
Securities Purchase Agreement [Member] | Common Stock [Member] | H.C. Wainwright & Co. LLC [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issued shares							31,231
Share price per share							$ 4.0625
Securities Purchase Agreement [Member] | Common Stock [Member] | Wainwright [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share price per share											$ 2.75
H.C. Wainwright & Co. LLC [Member] | Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issued shares		78,333
Share price per share		$ 1.875
Litigation Settlement [Member] | Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issued shares																						1,005,965				1,005,965
At-the-Market Offering Agreement [Member] | Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issued shares																			685,800
Aggregate offering price value	$ 4,820,000
Gross proceeds																			$ 734,000
[1]Net of issuance costs in the amount of approximately $ 328 333 1,075 676

SCHEDULE OF POTENTIALLY DILUTIV

SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES EXCLUDED FROM DILUTED LOSS PER SHARE (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from diluted loss per share	2,095,362	1,507,137
Series A (2013) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from diluted loss per share		183
Warrant To Underwriters December One Two Thousand Nineteen [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from diluted loss per share		45,643
Warrant To Underwriters December Two Two Thousand Nineteen [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from diluted loss per share		47,619
Warrant To Underwriters December Three Two Thousand Nineteen [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from diluted loss per share		45,045
Series A And B Warrant October Two Thousand Twenty Two [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from diluted loss per share	1,022,495	2,044,990
Warrant To Underwriters October Two Thousand Twenty Two [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from diluted loss per share	51,125	51,125
Warrant To Underwriters One May Two Thousand Twenty Three [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from diluted loss per share	32,778
Warrant To Underwriters Two May Two Thousand Twenty Three [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from diluted loss per share	60,476
Warrant To Underwriters June Two Thousand Twenty Three [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from diluted loss per share	35,088
Warrant Series C June Two Thousand Twenty Three [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from diluted loss per share	350,878
Warrant To Underwriters June Two Thousand Twenty Three Two [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from diluted loss per share	31,231
Warrant Series D June Two Thousand Twenty Three [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from diluted loss per share	312,309
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from diluted loss per share	2,095,362	1,507,137

SCHEDULE OF RESEARCH AND DEVELO

SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Share-based compensation			$ 1,067	$ 1,097	$ 1,394	$ 1,752
Research and development expense	$ 2,060	$ 1,612	$ 4,646	$ 4,594	(5,724)	(7,736)
Research and Development Expense [Member]
Payroll and related expenses					2,455	3,558
Share-based compensation					407	387
Professional services					1,842	2,097
Materials					520	559
Patents					157	341
Rent					213	224
Office and maintenance expenses					55	100
Depreciation					106	102
Other					248	368
Less - grants					(279)
Research and development expense					$ 5,724	$ 7,736

SCHEDULE OF GENERAL AND ADMINIS

SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Share-based compensation			$ 1,067	$ 1,097	$ 1,394	$ 1,752
General and administrative expenses	$ 1,240	$ 932	$ 3,549	$ 3,193	(4,131)	(5,545)
General and Administrative Expense [Member]
Payroll and related expenses					1,223	1,813
Government fees					58	35
Share-based compensation					988	1,365
Professional services					1,204	1,154
Insurance					442	733
Public and investor relations					148	220
Office and maintenance expenses					95	120
Travel					160	180
Other					94	81
Less – insurance loss recoveries					(281)	(156)
General and administrative expenses					$ 4,131	$ 5,545

SCHEDULE OF DEFERRED TAX ASSETS

SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 115,778	$ 113,393
Operating lease liabilities	53	105
Accrued vacation pay	59	71
Legal settlement accrual	464
Advance payment from IIA	17
Total deferred tax assets	116,371	113,569
Less: valuation allowance	(116,014)	(113,455)
Net deferred tax assets	357	114
Operating leases, right-of-use assets	(60)	(114)
Grant receivable (Ministry of Economy)	(5)
Insurance recovery receivable	(280)
Marketable securities	(12)
Total deferred tax liabilities	(357)	(114)
Total net deferred tax assets

TAXES ON INCOME (Details Narrat

TAXES ON INCOME (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
US Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Corporate income tax rate	21%	21%
Net operating loss carryforwards	$ 506,317	$ 502,053
Israel Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Corporate income tax rate	23%	23%
Net operating loss carryforwards	$ 41,164	$ 34,688

SCHEDULE OF FINANCIAL ASSETS FA

SCHEDULE OF FINANCIAL ASSETS FAIR VALUE MEASUREMENT (Details) - Marketable Securities [Member] - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Assets, fair value	$ 3,859	$ 3,917	$ 5,760
US Treasury Securities [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Assets, fair value		2,497	3,761
Money Market Funds [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Assets, fair value		1,420	1,999
Fair Value, Inputs, Level 1 [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Assets, fair value	3,859	3,917	5,760
Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Assets, fair value		2,497	3,761
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Assets, fair value		1,420	1,999
Fair Value, Inputs, Level 2 [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Assets, fair value
Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Assets, fair value
Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Assets, fair value
Fair Value, Inputs, Level 3 [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Assets, fair value
Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Assets, fair value
Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Assets, fair value

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Feb. 29, 2024

Jan. 26, 2024

Dec. 29, 2023

Jun. 06, 2023

Oct. 03, 2022

Oct. 31, 2024

Feb. 29, 2024

Sep. 30, 2024

Jun. 30, 2024

[1]

Mar. 31, 2024

Jun. 30, 2023

[2]

Sep. 30, 2024

Dec. 31, 2023

Dec. 31, 2022

Jun. 29, 2023

Jun. 26, 2023

May 31, 2023

Oct. 25, 2022

Subsequent Event [Line Items]

Existing investment options

$ 2,730,000

Gross proceeds from cash fee percentage

7%

Gross proceeds from management fee percentage

1%

Litigation settlement amount

$ 2,154,000

Legal settlement accrual

$ 2,211,000

$ 1,335,000

Settlement amount recovery

1,100,000

Legal expense

235,000

Non operating loss on legal settlement

$ 1,111,000

Annual bonus

$ 99,000

Common Stock [Member]

Subsequent Event [Line Items]

Issuance of common stock and warrants net of issuance costs, shares

1,566,669

1,685,682

[2]

3,576,689

3,816,689

[3]

782,495

[4]

Litigation Settlement [Member]

Subsequent Event [Line Items]

Payment for litigation settlement

$ 1,100,000

$ 1,100,000

Restricted common shares issued for legal settlement

1,005,965

Litigation Settlement [Member] | Common Stock [Member]

Subsequent Event [Line Items]

Issuance of common stock and warrants net of issuance costs, shares

1,005,965

1,005,965

At-the-Market Offering Agreement [Member] | Common Stock [Member]

Subsequent Event [Line Items]

Issuance of common stock and warrants net of issuance costs, shares

685,800

Total gross proceeds

$ 734,000

Subsequent Event [Member]

Subsequent Event [Line Items]

Litigation settlement amount

$ 2,154

Annual bonus

99

Payroll expenses

$ 140

$ 140

Subsequent Event [Member] | Common Stock [Member]

Subsequent Event [Line Items]

Issuance of common stock and warrants net of issuance costs, shares

77,500

Share price per share

$ 1.2684

$ 1.2684

Number of options vested

79,567

Subsequent Event [Member] | Litigation Settlement [Member]

Subsequent Event [Line Items]

Payment for litigation settlement

$ 1,100

Restricted common shares issued for legal settlement

1,005,965

Subsequent Event [Member] | At-the-Market Offering Agreement [Member] | Common Stock [Member]

Subsequent Event [Line Items]

Issuance of common stock and warrants net of issuance costs, shares

280,908

Total gross proceeds

$ 285,000

Chief Executive Officer [Member]

Subsequent Event [Line Items]

Share price per share

$ 1.25

$ 1.25

Cost reduction plan

50%

Agggregate number of options granted

79,567

Chief Executive Officer [Member] | Common Stock [Member]

Subsequent Event [Line Items]

Agggregate number of options granted

80,000

Weighted average exercise price per share

$ 2.43

Director [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Agggregate number of options granted

130,000

Director [Member] | Subsequent Event [Member] | Common Stock [Member]

Subsequent Event [Line Items]

Issuance of common stock and warrants net of issuance costs, shares

132,500

Share price per share

$ 1.2684

$ 1.2684

Weighted average exercise price per share

$ 1.25

Preferred Investment Option Exercise Inducement Offers Letter [Member]

Subsequent Event [Line Items]

Issuance of common stock and warrants net of issuance costs, shares

1,022,495

350,878

Options exercise price per share

$ 2.20

Share price per share

$ 2.075

$ 1.62

$ 3.19

Options to purchase an aggregate

1,685,682

Preferred Investment Option Exercise Inducement Offers Letter [Member] | H.C. Wainwright & Co. LLC [Member]

Subsequent Event [Line Items]

Issuance of common stock and warrants net of issuance costs, shares

84,284

Share price per share

$ 2.025

Gross proceeds from cash fee percentage

7%

Gross proceeds from management fee percentage

1%

Non-accountable expenses

$ 60

Clearing fees

$ 16,000

Inducement Investment Option [Member]

Subsequent Event [Line Items]

Share price per share

$ 1.50

[1]Net of issuance costs in the amount of approximately $ 328 333 1,075 676